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ABSTRACT 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, predominantly 
affecting women of childbearing age. The pathogenesis of SLE is multifactorial, and the 
clinical phenotype and course vary considerably within the SLE population. Multiple organs 
can be involved, lupus nephritis (LN) being one of the most severe manifestations. 
Immunologic abnormalities constitute a hallmark of SLE, and hyperactivity of the B cell 
lineage plays an important role in the pathogenesis, resulting in a prominent production of 
autoantibodies to nuclear components and immune complex depositions. 
The heterogeneity of SLE makes its management and the development of new therapies 
challenging. Belimumab is a monoclonal antibody targeting the B cell activating cytokine 
BAFF, also known as BLyS, approved for the treatment of SLE.  
In the studies included in this thesis, we focused on biomarkers in lupus nephritis and effects 
of belimumab treatment in SLE. For the purpose of the first part, immune components that 
have been implied to be important in lupus nephritis were evaluated as biomarkers of activity, 
response to treatment and long-term prognosis. In the second part, we investigated the clinical 
and immunologic effects of belimumab in a prospective, real-life clinical setting. 
We identified an association of antiphospholipid antibodies with short-term renal function 
impairment during LN flares, but we found no association with the long-term renal prognosis. 
In contrast, soluble TNF receptor 2 was predictive of kidney tissue damage and long-term 
renal function deterioration. Soluble TNF receptor 2 was shown to predict treatment response 
in patients with membranous nephritis, whereas a role of APRIL, a plasma cell survival 
cytokine, was implicated in proliferative glomerulonephritis. Finally, low baseline serum 
concentrations of BLyS were predictive of response to induction treatment for LN. 
We demonstrated decreased disease activity and corticosteroid usage, and no significant 
damage progression in patients with SLE during belimumab treatment. We observed rapid 
effects on naïve B cells and B cells of earlier developmental stages, whereas later stage B 
cells showed delayed or no changes. High baseline disease activity and steroid dose were 
associated with beneficial treatment outcomes, whereas smoking and established organ 
damage predicted reduced treatment efficacy. While high BLyS levels predicted clinical 
improvements, high B cell counts predicted unfavourable outcomes, implying that patients 
with a high B cell activity and, therefore, suppressed BLyS activity may benefit from B cell 
depletion preceding BLyS inhibition. 
Based on our results from the studies of belimumab, smokers who qualify for treatment with 
this biologic agent should actively be encouraged to quit smoking. An important implication 
for the use of belimumab is that early treatment evaluation might underestimate delayed 
clinical improvements occurring as a consequence of late therapy-associated B cell changes.  
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1 INTRODUCTION 
 
1.1 SYSTEMIC LUPUS ERYTHEMATOSUS 
 
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease, 
characterised by a relapsing-remitting course with flares and periods of low disease activity 
or remission. The prevalence of SLE varies in different populations ranging from 0.04% to 
0.2%, depending on, inter alia, ethnicity [1]. SLE predominantly affects women, with a 
generally estimated female-to-male ratio of 9:1 [2]. 
Despite pharmacological advances and increased survival rates [3-5] compared to estimations 
in the middle of last century [6], SLE is still associated with premature mortality [7-10], 
especially in developing countries [11, 12], with an estimated 15-year survival rate of 
approximately 80% [5]. 
The pathogenesis of SLE is multifactorial and its aetiology is largely unknown [13]. Genes, 
ethnicity, hormones and environmental factors have been implicated among the causes and 
pathological mechanisms underlying the disease. Multiple organs may be involved, including 
the skin, joints, kidneys and central nervous system. The variation in severity is considerable, 
ranging from mild to severe manifestations, and sometimes organ- or life-threatening 
conditions. While mortality during the early course of SLE is associated with disease activity 
and infections, comorbid conditions, cardiovascular events in particular, are important causes 
of death at later stages [1]. 
Dysfunction of the immune system is a hallmark of SLE. Both the innate and the adaptive 
immunity may be aberrant, and defective apoptotic cell clearance has been hypothesised as a 
central phenomenon underlying the initiation of autoreactive responses. Type I interferon 
(IFN) has been suggested to play a central role in the pathogenesis of SLE, initially based on 
observations showing that treatment with IFN-α induced autoimmunity in patients with 
malignancies [14].  
The hyperactivity of the B cell lineage, including plasma cells, plays a pivotal role in the 
pathogenesis of SLE. The disease is characterised by a prominent production of 
autoantibodies to nuclear components and immune complex depositions, resulting in 
inflammation and subsequent damage in organs and tissues. Autoantibodies that have been 
identified in patients with SLE include antinuclear antibodies (ANA), anti-double-stranded 
DNA (anti-dsDNA), anti-SSA (or anti-Ro), anti-SSB (or anti-La), anti-ribonuclear protein 
(anti-RNP), anti-C1q, anti-Smith (anti-Sm), and antiphospholipid antibodies (aPL) [15, 16]. 
Although a better understanding of autoimmunity in SLE has been achieved, reliable 
biomarkers of disease activity and treatment response have yet to be discovered.  
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The management of SLE and the development of new therapies have been challenging 
because of the prominent heterogeneity of the disease in clinical presentation and underlying 
immunopathology, as well as its unpredictable course and response to treatment. For these 
reasons, the treatment of SLE varies and is highly individualised. Commonly used therapies 
include corticosteroids, antimalarial agents, immunosuppressive agents and non-steroidal 
anti-inflammatory drugs (NSAIDs) [17, 18]. In March 2011, the US Food and Drug 
Administration (FDA) approved belimumab as a new treatment for patients with SLE. Later, 
belimumab was approved for the treatment of SLE in the EU and in other countries [19, 20]. 
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1.2 CLASSIFICATION OF SLE 
 
The heterogeneity of SLE is one of the main reasons why no diagnostic criteria have been 
developed. However, classification criteria have been developed and are widely used, mostly 
for inclusion of homogenous patient groups in clinical trials and in longitudinal observational 
studies. The first classification criteria were published in 1971. Later, a revised version was 
published in 1982 (Table 1.1) [21].  
The 1982 American College of Rheumatology (ACR) criteria for classification of SLE are 
based on common clinical features and laboratory findings of the disease, and provide a list 
of definitions, one for each criterion. The list includes eleven criteria, nine of which are 
clinical and two of which are immunologic. For classification of SLE, at least four criteria 
have to be met.  
In 1997, a modification of these classification criteria was proposed, according to which 
positive lupus erythematosus (LE) cells were excluded and antiphospholipid antibodies (aPL) 
were added [22]. However, the 1982 revised criteria are still more commonly used for 
research purposes compared to the 1997 updated criteria. 
More recently, the Systemic Lupus International Collaborating Clinics (SLICC) group 
revised and validated the ACR classification criteria in order to improve their clinical 
relevance and incorporate new knowledge regarding the immunology of SLE [23]. The new 
SLICC classification criteria (Table 1.2) were found to perform better in terms of sensitivity, 
but not specificity, compared to the revised 1997 ACR criteria.  
According to the new SLICC criteria, the patient has to satisfy at least four criteria, including 
at least one clinical criterion and one immunologic criterion. An exception is biopsy-proven 
lupus nephritis, which along with the presence of antinuclear antibodies or anti-dsDNA 
antibodies is sufficient for classification.  
The requirement for at least one clinical and at least one immunologic criterion reflects the 
opinion of the SLICC group that neither clinical criteria alone nor positive serologic test 
results alone should be sufficient for classification of SLE. In the new criteria, malar rash and 
photosensitivity are no longer two separate items, as they are largely overlapping, and non-
scarring alopecia has been added. The arthritis criterion is redefined to include erosive 
arthritis, and the renal criterion includes the measurement of proteinuria using the urinary 
protein to creatinine ratio (UPCR).  
The incorporation of the new SLICC criteria may prove important in clinical trials and 
observational studies, as they allow the inclusion of patients with specific phenotypes that are 
excluded from the ACR criteria, and thus increase the numbers of participating patients. 
However, the fact that they display a lower specificity compared to the older 1997 ACR 
criteria might be one of the reasons why the SLICC criteria have not received full recognition 
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to date. Still, they have been used in recently published and several ongoing clinical trials of 
new therapies, which is likely to increase their use. 
 
Table 1.1. The 1982 revised ACR criteria for classification of SLE  
No Criterion Definition 
1 Malar rash Fixed erythema, flat or raised, over the malar eminences 
2 Discoid rash Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions 
3 Photosensitivity Skin rash as a result of unusual reaction to sunlight 
4 Oral ulcers Oral or nasopharyngeal, usually painless, observed by a physician 
5 Arthritis Non-erosive arthritis involving two or more peripheral joints 
6 Serositis a. Pleurisy 
b. Pericarditis 
7 Renal a. Persistent proteinuria greater than 0.5 g/day or greater than 3+ if 
quantification not performed, or 
b. Cellular casts: red cell, haemoglobin, granular, tubular, or mixed 
8 Neurologic Seizures or psychosis, in the absence of other causes 
9 Haematologic a. Haemolytic anaemia: with reticulocytosis, or 
b. Leukopenia: <4,000 cells/mm3 on 2 or more occasions, or 
c. Lymphopenia: <1,500 cells/mm3 on 2 or more occasions, or 
d. Thrombocytopenia: <100,000 cells/mm3 in the absence of 
offending drugs 
10 Immunologic a. Positive LE cell preparation, or 
b. Anti-DNA: antibody to native DNA in abnormal titre, or 
c. Anti-Sm: presence of antibody to Sm nuclear antigen, or 
d. False positive serologic test for syphilis, known to be positive 
for at least 6 months and confirmed by Treponema pallidum 
immobilisation or fluorescent treponemal antibody absorption 
11 ANA Abnormal titre of ANA at any point in time and in the absence of 
drugs associated with drug-induced lupus syndrome 
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Table 1.2. The SLICC classification system for SLE 
Clinical criteria 
1 Acute or subacute cutaneous lupus 
2 Chronic cutaneous lupus 
3 Oral or nasal ulcers, in the absence of other causes 
4 Non-scarring alopecia, in the absence of other causes 
5 Synovitis, involving at least 2 joints 
6 Serositis, in the absence of other causes 
7 Renal: UPCR or 24-hour urine protein representing 0.5 g/day, or red blood cell casts 
8 Neurologic: seizures, psychosis, mononeuritis multiplex, myelitis, peripheral or 
cranial neuropathy, or acute confusional state 
9 Haemolytic anaemia 
10 Leucopenia (<4,000/mm3) or lymphopenia (<1,000/mm3) 
11 Thrombocytopenia (<100,000/mm3) 
Immunologic criteria 
1 ANA 
2 Anti-dsDNA 
3 Anti-Sm 
4 Antiphospholipid antibodies: lupus anticoagulant and/or false-positive test result for 
rapid plasma reagin and/or medium or high anticardiolipin antibody level (IgA, IgG or 
IgM) and/or positive test result for anti-β2-glycoprotein I (IgA, IgG or IgM) 
5 Low complement: low C3 and/or low C4 and/or low CH50 
6 Direct Coombs’ test, in the absence of haemolytic anaemia 
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1.3 B CELL ABNORMALITIES IN SLE 
 
The peripheral blood composition of SLE patients can deviate considerably from that of 
healthy individuals [24]. Failure of self-tolerance checkpoints, normally functioning to limit 
autoreactive B cells, and the subsequent autoantibody production are considered distinctive 
attributes of the disease [25]. Studies of B cell deficient lupus-prone mice have shown that B 
cells, but not necessarily autoantibodies, are required for the occurrence of lupus-like 
autoimmunity [26-28]. Defective maturation of B cells towards plasma cells has also been 
reported to be important in the induction of autoimmunity [29]. However, lupus-prone animal 
models genetically engineered to have peripheral B cells, though lacking the capacity of 
producing antibodies, including autoantibodies, have been shown to maintain their ability to 
develop lupus-like autoimmunity features. This underscores the necessity of B cells in the 
induction of autoimmunity due to a variety of characteristics apart from the ability to produce 
autoantibodies, e.g. promoting T cell activation via antigen presentation [26, 30]. However, 
data from mouse studies should always be interpreted with caution, as only specific 
mechanisms are reproduced rather than the entire pathophysiology of the disease, and 
important interactions may therefore be omitted or deceptive. This is of vital importance, 
especially when studying SLE, which is known for its heterogeneity and complexity. 
In humans, linkage analysis, candidate gene studies and genome-wide association studies 
have identified associations of genetic loci encoding proteins that are critical for B cell 
differentiation and proliferation with SLE susceptibility [31].  
B cells recognise their environment through interactions between receptors on their surface 
and ligands. These interactions instigate intracellular pathways mediated by enzymes and 
adaptor proteins, resulting in genotypic and phenotypic modifications [32]. Apart from their 
role in educating themselves towards highly specific antibody production, B cells are also 
important as cytokine-secreting and antigen-presenting cells. Their main receptor is the B cell 
receptor (BCR) complex, which consists of  
i. a membrane-bound immunoglobulin functioning as the antigen-binding moiety of the 
receptor, and 
ii. an intracytoplasmic signal transduction moiety comprising a heterodimer composed 
of two disulphide-linked proteins, Ig-α and Ig-β (CD79). 
Binding of an antigen to the membrane immunoglobulin domain of the BCR causes 
phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) domains of 
the Ig-α and Ig-β proteins. This phenomenon is catalysed by kinases of the Src family, Lyn 
being a critical tyrosine-protein kinase among them. This action brings about a cascade of 
signalling events, such as the subsequent recruitment and activation of other kinases, 
including Syk, eventually resulting in more distal transduction processes and gene 
transcription modifications in the nucleus [33]. The final signal initiated by the BCR is fine-
tuned by co-receptors and other adjunct molecules, including CD19, a positive signal 
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regulator, and CD22 and FcγRIIB, negative signal regulators. Moreover, critical for B cell 
survival and homeostasis are two members of the tumour necrosis factor (TNF) ligand 
superfamily, B lymphocyte stimulator (BLyS, also known as BAFF) and a proliferation-
inducing ligand (APRIL) [34], further discussed in chapter 1.7.2.  
In patients with SLE, B cell signalling is aberrant. Studies have shown altered signal 
transduction events, including augmented cytoplasmic free calcium responses and 
phosphorylation of tyrosine-protein residues following BCR interaction with anti-human IgM 
and IgD antibodies [35-37]. Whether this altered hyperactive B cell phenotype is due to 
intrinsic molecular defects or effects of exogenous factors, or both, has been addressed in 
studies of animal models and small molecules inhibiting intracellular mediators of B cell 
signalling pathways, such as Lyn, Syk, PI3Ks, and Btk [38-58].  
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1.4 LUPUS NEPHRITIS 
 
Organs and tissues that may be affected in patients with SLE during the course of the disease 
include the skin, kidneys, central nervous system (CNS), pleurae, pericardium, red and white 
blood cells, platelets, blood vessels and joints (Figure 1.1). The patients may also experience 
a wide array of general symptoms, including fatigue, fever, arthralgia, myalgia and weight 
loss. As Paper I, Paper II and Paper III in this thesis focus on renal involvement, lupus 
nephritis (LN) in particular, an elaborate description of this particular manifestation is 
presented in this chapter.  
The kidneys are involved in a significant fraction of patients with SLE, ranging from 35% to 
60% of the SLE population depending on demographical diversities. LN constitutes one of 
the most severe organ manifestations of SLE, and occurs more frequently in juvenile-onset 
compared to late-onset SLE. Most SLE patients, especially children and adolescents, develop 
LN early during the course of their disease, within five years from diagnosis. However, 
development of LN at later time points is not uncommon, and regular monitoring of the renal 
function is suggested during the entire course of the disease. In many cases, LN is the 
manifestation resulting in the diagnosis of SLE [59-61].  
Despite increased knowledge of the pathogenesis and improved treatment regimens, LN 
remains a substantial cause of morbidity among patients with SLE [61]. In a study of 156 LN 
patients followed between 1975 and 2005, the 5-year mortality rate was found to have 
decreased by 60% between the first and second decades while it remained stable over the 
third decade. The 5-year end-stage renal disease (ESRD) rate remained unchanged, the 
number of renal transplantations was found to increase, and patients of Afro-Caribbean origin 
exhibited a poorer overall prognosis [62]. These results suggest that the benefits of current 
therapies are maximised, and novel drug regimens are needed in order to achieve further 
improvement. 
Compared to the general SLE population, LN patients display higher morbidity and mortality 
rates [61, 63]. Conventional immunosuppressive treatments are not effective in all LN cases 
and, even in patients who respond, they have been shown to be insufficient to hamper relapse 
in 35% of the cases. Moreover, 5–20% of the patients with LN develop ESRD within 10 
years from the initial event, and drug-induced toxicity remains a concern [64-66]. Early and 
accurate diagnosis of LN and prompt initiation of induction therapy are therefore of vital 
importance. The current gold standard for the diagnosis and classification of LN is the renal 
biopsy. However, given the potential risks of this procedure, it is necessary to identify 
biomarkers for tracking renal activity and predicting treatment outcome. 
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1.4.1 Clinical features and definition 
 
Proteinuria is the most common feature of LN. The clinical presentation and the laboratory 
findings may vary, ranging from asymptomatic cases (silent LN) to severe proteinuria and 
nephrotic syndrome (proteinuria levels of >3.5 g/day) or acute nephritic syndrome, in several 
cases resulting in acute renal failure. However, the patients most commonly present with a 
mild proteinuria and/or haematuria and/or pyuria. The urinary sediment often reveals activity, 
with findings including cellular casts. Occasionally, patients may present with chronic renal 
failure or isolated renal insufficiency. Hypertension may sometimes be the initial sign [67].  
According to the 1982 revised ACR criteria for classification of SLE (Table 1.1), renal 
disorder is defined as 
i. persistent proteinuria greater than 0.5 g/day or greater than 3+ according to dipstick 
measurement if quantification has not been performed, and/or 
ii. cellular casts: red cell, haemoglobin, granular, tubular, or mixed [21]. 
According to the more recent SLICC classification criteria, renal disorder is defined as  
i. a urinary protein to creatinine ratio (UPCR) or a 24-hour urine protein excretion 
representing a 0.5 g urinary protein excretion per day or more, and/or 
ii. red blood cell casts [23]. 
 
1.4.2 Pathogenesis of LN 
 
The pathological mechanisms underlying the inflammatory renal injury in SLE are not fully 
understood. Like SLE in general, LN involves a broad spectrum of immunologic 
mechanisms. Immune complexes (ICs), molecules formed by the integral binding of 
antibodies to soluble antigens, are considered key mediators of various immune responses, 
and T cells, macrophages, dendritic cells and an array of cytokines are involved in the 
pathogenesis and progression of LN (Figure 1.2).  
 
1.4.2.1 The role of autoantibodies 
 
Autoantibodies are believed to be essential for the development of LN, and anti-dsDNA and 
anti-nucleosome antibodies are the ones most associated with the pathogenesis [68]. 
However, antibodies to Sm, SSA, SSB, C1q and multiple other antigens have also been 
demonstrated to be organised in glomerular IC deposits in renal tissue from patients with SLE 
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[69]. Early immunologic surveys implicated the involvement of autoantibodies in the 
development of glomerulonephritis in SLE [70]. Subsequent human and animal studies 
substantiated the hypothesis that anti-dsDNA antibodies were critical for the pathogenesis of 
LN [71-75].  
Although high avidity anti-dsDNA antibodies have been suggested to be pathogenic and the 
screening methods have undergone advances [76], not all patients with persistently high 
levels of anti-dsDNA develop LN [77] and experiments in murine lupus have shown no clear 
relationship between the affinity of antibodies with dsDNA and their ability to cause 
glomerulonephritis [72-74]. Comparing isotypes, IgG-class anti-dsDNA antibodies have been 
shown to induce lupus-like glomerulonephritis in murine models [72, 78], whereas anti-
dsDNA antibodies of the IgM isotype are considered less specific for SLE and their 
pathogenic relevance has yet to be elucidated. Previous research has demonstrated that IgM 
anti-dsDNA antibodies do not correlate with SLE activity [79, 80], and more recent studies 
have reported negative correlations between IgM anti-dsDNA antibodies and 
glomerulonephritis [81, 82] and even a protective role of IgM anti-dsDNA against IC-
mediated organ damage [83-85]. To date, only a few studies have evaluated the role of IgA 
anti-dsDNA antibodies in the diagnosis and monitoring of SLE and LN, and the results are 
conflicting [86-89]. 
Furthermore, specific SLE-associated autoantibodies with apparent specificity for dsDNA 
have been demonstrated to bind chromatin but not pure DNA, and were in fact anti-
nucleosome antibodies [90, 91]. In addition, nucleosomal material was demonstrated to 
mediate the binding of autoantibodies to the glomerular basement membrane, and complexes 
of anti-nucleosome antibodies with nucleosomal antigens were found to exhibit anti-DNA 
reactivity [92]. It has therefore been proposed that a major determinant of the pathogenicity 
of autoantibodies in LN might be their binding to nucleosomes [92-94]. 
Antibodies to C1q are detected in 30–60% of the patients with SLE, and studies have 
reported associations with renal involvement [95, 96]. Binding of these autoantibodies to ICs 
in glomeruli containing C1q has been shown to induce renal disease [97], and high titres have 
been found to be associated with histological features of active LN [98]. In recent years, 
particular emphasis has been given to a potentially pathogenic role of anti-α-actinin 
antibodies in LN based on several murine and human studies [99-103], but data from other 
studies have not been supportive of this hypothesis [104, 105].  
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1.4.2.2 The role of immune complexes 
 
Various mechanisms have been proposed to contribute to the formation of immune complex 
deposits in glomeruli of LN patients, including 
i. the deposition of circulating ICs (Figure 1.3),  
ii. direct binding to in situ renal antigens, such as laminin, heparin and annexin II, and 
iii. direct binding to endogenous circulating autoantigens, such as DNA or nucleosomes, 
having been localised within the kidney (planted antigen theory) [68, 106].  
These immune complexes can, in turn, lead to further activation of immune pathways through 
co-stimulation of Fcγ receptors and endosomal Toll-like receptors (TLRs) or through 
activation of the complement cascade [107]. 
Complement activation and deposition of complement proteins in glomeruli are known to 
have deleterious effects on the renal tissue in LN [108]. This is in contrast to the high 
prevalence of SLE among individuals with genetically determined complement component 
deficiency, resulting in impaired clearance of ICs and apoptotic material, and, in turn, 
tolerance cessation. In these individuals, complement activation would be expected to have 
protective effects, due to augmented clearance of ICs and cellular debris [109]. 
 
 
Figure 1.3. Graphic illustration of immune complexes 
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1.4.2.3 The role of aberrant cell functions 
 
Following formation and deposition of ICs in the kidney, tissue injury ensues from the 
interaction between resident renal cells and infiltrating inflammatory cells. The production of 
cytokines, chemokines and adhesion molecules leads to further infiltration of inflammatory 
cells and further production of proinflammatory cytokines, resulting in inflammation, injury, 
and fibrosis in the kidney.  
The role of T cells is important both in SLE and LN, demonstrating increased homing to the 
kidney [110-113]. T cells may contribute to the tissue injury through various mechanisms, 
including  
i. the activation of B cells, which, in turn, produce nephritogenic antibodies,  
ii. the recruitment of macrophages and dendritic cells, and  
iii. the production of  a wide array of proinflammatory cytokines [114-117]. 
In murine lupus, T cell depletion and inhibition of T cell activation have been shown to 
hamper the progression of nephritis [118, 119]. 
Various functions of pathogenic B cells are also implicated in the pathogenesis of LN, 
including the production of potentially nephritogenic autoantibodies, cytotoxicity mediated 
by interactions with complement components, and release of inflammatory mediators. Studies 
of murine lupus have shown that infiltrating B cells in renal tissue secrete antibodies with 
various antigen specificities and contribute to increased in situ ICs [120-122]. Further, 
germinal centre-like structures and aggregates of T cells and B cells in the kidney have been 
shown to promote in situ secretion of pathogenic antibodies and ICs in patients with SLE 
[123-125]. B cell depletion has been shown to prevent or delay the onset of 
glomerulonephritis in lupus-prone mice [26, 27, 126, 127] and induce complete or partial 
clinical remission in LN patients [128-134]. Lupus-prone mice in which the ability of B cells 
to secrete antibodies had been impeded were demonstrated to develop nephritis [30], 
implying that B cell functions other than antibody production, e.g. antigen presentation and 
cytokine production, also contribute to inflammatory renal injury.  
Neutrophils, macrophages, and dendritic cells are also believed to contribute to renal injury. 
Self-antigens, such as histones and DNA incorporated in neutrophil extracellular traps 
(NETs), have been detected in IC deposits in the renal tissue of SLE patients [135-138]. 
Patients with SLE have an aberrant subpopulation of neutrophils, with a propensity for 
NETosis, a process of cellular death, during which nuclear and cytoplasmic material is 
extruded from the cell to be disposed as web-like structures containing potential autoantigens, 
as well as proinflammatory cytocines, enzymes, et cetera. This process may be driven by 
various stimuli, including oxidative stress and infectious organisms. In SLE, NETosis has 
been shown to contribute to the type I IFN signature through stimulating IFN production by 
plasmacytoid dendritic cells [136, 139] (Figure 1.2).  
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Dendritic cells and macrophages contribute through production of proinflammatory 
cytokines, expression of chemokine receptors and interactions with autoreactive T cells, 
resulting in the recruitment of additional inflammatory cells. Reduction of CD11c+ dendritic 
cells in lupus-prone mice has been shown to ameliorate renal disease features [140], and the 
presence of plasmacytoid dendritic cells correlated with increased interleukin (IL)-18 
expression in the glomeruli of patients with active nephritis [141]. Activated macrophages 
have been demonstrated to be associated with the onset of proteinuria in mice [142-144], and 
macrophage infiltration in renal tissue has been shown to be associated with disease activity 
in SLE patients with nephritis [145, 146]. 
 
1.4.2.4 The role of cytokines and chemokines 
 
The clinical features of nephritis, e.g. proteinuria, are preceded by inflammatory cell 
infiltration driven by the production of cytokines and chemokines. Cytokines that have been 
implicated in LN include IL-12, IL-17, IL-18, IL-23, IFN-γ and IFN-λ [141, 147-157]. 
Chemokines and growth factors that have been demonstrated to be upregulated in SLE-
associated kidney disease include the monocyte chemoattractant protein-1 (MCP-1; 
chemokine (C-C motif) ligand 2, CCL2), the macrophage inflammatory protein-1β (CCL4), 
the RANTES chemokine (CCL5), the macrophage colony-stimulating factor and the IFN-γ-
induced protein-10 (CXCL10) [158-166]. In lupus-prone mice, MCP-1 levels have been 
shown to increase as nephritis progresses, and MCP-1 blockade in the background of 
nephritis has been demonstrated to ameliorate renal disease features and decrease T cell and 
macrophage renal infiltration. In patients with LN, tubulointerstitial expression of MCP-1 has 
been shown to be associated with chronic renal damage [150], and urinary MCP-1 levels 
have been demonstrated to be associated with renal disease activity [164, 166].  
 
1.4.3 The value of renal biopsies 
 
To date, the renal biopsy is the gold standard for the evaluation and classification of LN. 
Histological findings in renal biopsies determine the grade of the inflammatory activity and 
the extent of chronic damage, and provide the treating physician with useful information and 
guidance during decision-making. Importantly, based on histological findings one can 
identify conditions other than LN that may affect the kidneys in patients with SLE and 
clinically mimic LN [167-170], e.g. IgA nephropathy, diabetic nephropathy, antiphospholipid 
antibody-associated nephropahy, hypertensive nephrosclerosis and thin basement membrane 
disease. 
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1.4.3 The value of renal biopsies 
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Neither clinical evaluation nor laboratory findings can accurately reflect the histological 
patterns of LN. Biomarker studies have therefore been of particular interest towards the 
development of non-invasive diagnostic and prognostic tools, in order to avoid the potential 
adverse events following renal biopsies, even though they are rare and most often self-
limiting [171]. It is recommended that a renal biopsy should be performed in cases of 
persistent proteinuria of more than 0.5 g/day, especially when accompanied by haematuria 
and/or cellular casts in the urinary sediment, but it could also be considered in cases of 
persisting isolated haematuria or pyuria after exclusion of other causes, e.g. infections, or 
unexplained renal insufficiency accompanied by normal urinary findings [67, 168].  
Patients with refractory LN and persistent proteinuria or renal function deterioration despite 
treatment should be evaluated for other possible causes, including the nephrotoxic side effects 
of medications, e.g. calcineurin inhibitors and NSAIDs, renal vein thrombosis, infections, 
poorly-controlled hypertension and suboptimal compliance with treatment. A post-treatment 
renal biopsy should be considered in patients with persistently active serologic markers, as it 
may provide information that is omitted in clinical and laboratory evaluation, such as  
i. possible histological LN class transformations,  
ii. the degree of residual renal activity, 
iii. the extent of chronic, irreversible changes, representing tissue damage, and  
iv. renal damage progression since the initiation of immunosuppressive treatment [67].  
A recent study found that a significant fraction of patients who had attained response to 
induction treatment based on widely used clinical response criteria still had histological 
findings consistent with active renal disease in post-treatment renal biopsies [172]. This 
information is important for the decision of future treatment strategies and follow-up 
management.  
 
1.4.4 Histological classification 
 
A thorough examination of a renal biopsy should include light microscopy (LM), 
immunofluorescence (IFL), and electron microscopy (EM). The histological information 
obtained from a renal biopsy is considered adequate when a minimum of ten glomeruli has 
been analysed. Several patterns of renal disease may be observed, including glomerular, 
tubulointerstitial and vascular pathology. In terms of terminology, LN refers to IC-mediated 
renal injury, and positive staining for deposits including IgG, IgA, IgM, C1q, C3, and C4 is 
expected [67, 173]. 
Although LN may involve all compartments of the kidney, the classification systems of LN 
that have been used to date are based only on glomerular findings. The first World Health 
Organisation (WHO) classification of LN was introduced in 1974 (Table 1.3) [174]. 
 
17 
Neither clinical evaluation nor laboratory findings can accurately reflect the histological 
patterns of LN. Biomarker studies have therefore been of particular interest towards the 
development of non-invasive diagnostic and prognostic tools, in order to avoid the potential 
adverse events following renal biopsies, even though they are rare and most often self-
limiting [171]. It is recommended that a renal biopsy should be performed in cases of 
persistent proteinuria of more than 0.5 g/day, especially when accompanied by haematuria 
and/or cellular casts in the urinary sediment, but it could also be considered in cases of 
persisting isolated haematuria or pyuria after exclusion of other causes, e.g. infections, or 
unexplained renal insufficiency accompanied by normal urinary findings [67, 168].  
Patients with refractory LN and persistent proteinuria or renal function deterioration despite 
treatment should be evaluated for other possible causes, including the nephrotoxic side effects 
of medications, e.g. calcineurin inhibitors and NSAIDs, renal vein thrombosis, infections, 
poorly-controlled hypertension and suboptimal compliance with treatment. A post-treatment 
renal biopsy should be considered in patients with persistently active serologic markers, as it 
may provide information that is omitted in clinical and laboratory evaluation, such as  
i. possible histological LN class transformations,  
ii. the degree of residual renal activity, 
iii. the extent of chronic, irreversible changes, representing tissue damage, and  
iv. renal damage progression since the initiation of immunosuppressive treatment [67].  
A recent study found that a significant fraction of patients who had attained response to 
induction treatment based on widely used clinical response criteria still had histological 
findings consistent with active renal disease in post-treatment renal biopsies [172]. This 
information is important for the decision of future treatment strategies and follow-up 
management.  
 
1.4.4 Histological classification 
 
A thorough examination of a renal biopsy should include light microscopy (LM), 
immunofluorescence (IFL), and electron microscopy (EM). The histological information 
obtained from a renal biopsy is considered adequate when a minimum of ten glomeruli has 
been analysed. Several patterns of renal disease may be observed, including glomerular, 
tubulointerstitial and vascular pathology. In terms of terminology, LN refers to IC-mediated 
renal injury, and positive staining for deposits including IgG, IgA, IgM, C1q, C3, and C4 is 
expected [67, 173]. 
Although LN may involve all compartments of the kidney, the classification systems of LN 
that have been used to date are based only on glomerular findings. The first World Health 
Organisation (WHO) classification of LN was introduced in 1974 (Table 1.3) [174]. 
 18 
 
Table 1.3. The 1974 WHO classification of LN 
Class Definition 
I Normal glomeruli by LM, IFL and EM 
II Purely mesangial disease 
a. Normocellular mesangium by LM, but mesangial deposits by IFL or EM 
b. Mesangial hypercellularity with mesangial deposits by IFL or EM 
III Focal proliferative glomerulonephritis (<50% of the glomeruli) 
IV Diffuse proliferative glomerulonephritis (≥50% of the glomeruli) 
V Membranous glomerulonephritis 
 
The original 1974 WHO classification was modified in 1982 by the International Study of 
Kidney Diseases in Children [175]. In this modification (Table 1.4), class I was applied to 
normocellular glomeruli, but allowed mesangial immune deposits in class Ib, which was 
described as a subcategory of class II in the original classification. Class II was applied to 
purely mesangial proliferative glomerulonephritis. Class III comprised focal segmental 
glomerulonephritis, and class IV comprised diffuse glomerulonephritis. Moreover, 
subdivisions for class III and class IV were introduced, and were based on the presence of 
active, chronic, or mixed types of glomerular injury. Class V denoted membranous 
glomerulonephritis, but comprised subcategories based on the presence of mesangial 
hypercellularity and overlaps with focal or diffuse proliferative LN. A new class was 
introduced (class VI), which denoted advanced sclerosing glomerulonephritis [176]. 
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Table 1.4. The 1982 WHO modified morphologic classification of LN 
Class Definition 
I Normal glomeruli  
a. Normal by all techniques 
b. Normal by LM, but deposits by IFL or EM 
II Pure mesangial alterations (mesangiopathy)  
a. Mesangial widening and/or mild hypercellularity (+) 
b. Moderate hypercellularity (++) 
III Focal segmental glomerulonephritis associated with mild or moderate mesangial 
alterations 
a. with "active" necrotising lesions 
b. with "active" and sclerosing lesions 
c. with sclerosing lesions 
IV Diffuse glomerulonephritis: severe mesangial, endocapillary or mesangiocapillary 
proliferation and/or extensive subendothelial deposits 
a. without segmental lesions 
b. with "active" necrotising lesions 
c. with "active" and sclerosing lesions 
d. with sclerosing lesions 
V Diffuse membranous glomerulonephritis 
a. Pure membranous glomerulonephritis 
b. Associated with lesions of class II 
c. Associated with lesions of class III 
d. Associated with lesions of class IV 
VI Advanced sclerosing glomerulonephritis 
 
In 1995, the WHO classification was revised [177]. Attention was drawn to the significance 
of the extent of capillary wall necrosis within the glomeruli. A discrepancy between 
investigators was apparent regarding whether segmental glomerular necrosis should be a 
feature of class III regardless of the percentage of glomeruli involved.  
In order to eliminate inconsistencies and ambiguities, a new revised classification of LN was 
proposed by the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 
several years later [176]. Although this revised classification preserved the principles of the 
WHO classification, it incorporated refinements concerning activity and chronicity from the 
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1982 and 1995 revisions, as well as it introduced important modifications regarding 
quantitative and qualitative differences between class III and class IV (Table 1.5). Like in the 
preceding WHO classifications, vascular and tubulointerstitial pathology is not included and 
the classification is exclusively based on glomerular pathology. However, in the new 
classification it is explicitly stated that concurrent tubular atrophy, interstitial inflammation 
and fibrosis, as well as arteriosclerosis or other vascular lesions should be indicated and 
graded as mild, moderate, or severe [176]. 
 
Table 1.5. The 2003 ISN/RPS classification of LN 
Class Definition 
I Minimal mesangial LN 
II Mesangial proliferative LN 
III (A) Focal proliferative LN (active lesions) 
III (A/C) Focal proliferative and sclerosing LN (active and chronic lesions) 
III (C) Focal sclerosing LN (chronic inactive lesions with glomerular scars) 
IV-S (A) Diffuse segmental proliferative LN (active lesions) 
IV-G (A) Diffuse global proliferative LN (active lesions) 
IV-S (A/C) Diffuse segmental proliferative and sclerosing LN (active and chronic lesions) 
IV-G (A/C) Diffuse global proliferative and sclerosing LN (active and chronic lesions) 
IV-S (C) Diffuse segmental sclerosing LN (chronic inactive lesions with scars) 
IV-G (C) Diffuse global sclerosing LN (chronic inactive lesions with scars) 
V Membranous LN  
VI Advanced sclerosing LN 
 
In the 2003 ISN/RPS classification, class I is defined as a minimal mesangial LN, with 
normal glomeruli by LM, yet allowing mesangial immune deposits by IFL. Class II denotes 
mesangial proliferative LN, with purely mesangial hypercellularity of any degree, or 
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mesangial matrix expansion by LM with mesangial immune deposits (Figure 1.4). Cases with 
a few isolated subepithelial or subendothelial deposits visible by IFL or EM, but not by LM, 
may be included in this class. Class III is defined as an active or inactive focal, segmental or 
global endo- or extracapillary glomerulonephritis involving <50% of the glomeruli in the 
biopsy, typically with focal subendothelial immune deposits, with or without mesangial 
alterations (Figure 1.4). Class IV is defined as an active or inactive diffuse, segmental or 
global endo- or extracapillary glomerulonephritis involving ≥50% of the glomeruli, typically 
with diffuse subendothelial immune deposits, with or without mesangial alterations. Class IV 
is further divided into segmental (IV-S) and global (IV-G). Segmental lesions are defined as 
glomerular lesions involving less than half of the glomerular tuft, whereas global lesions 
involve at least half of the glomerular tuft. Diffuse segmental LN indicates that ≥50% of the 
involved glomeruli have segmental lesions, and diffuse global LN indicates that ≥50% of the 
involved glomeruli have global lesions. This class may include cases with diffuse wire loop 
deposits, but with little or no glomerular proliferation (Figure 1.4). Class V describes global 
or segmental continuous granular subepithelial immune deposits, or their morphologic 
sequelae, by LM and by IFL or EM, with or without mesangial alterations (Figure 1.4). It 
may occur in combination with class II, class III or class IV, and in such cases both classes 
should be reported. Development of segmental or global glomerulosclerosis is a typical 
finding as class V evolves. Finally, class VI is applied in cases of advanced sclerosis, when 
≥90% of the glomeruli are globally sclerosed without residual activity [176].  
The concept of active and chronic renal lesions was introduced in 1964 [178] and refined in 
1976 [179]. Several years later, a system of semiquantitative scores for activity and chronicity 
was proposed (Table 1.6). According to this system, specific morphologic components in a 
renal biopsy are evaluated as descriptors within two individual scores, one for activity and 
one for chronicity [180, 181]. Each item contributes to the total score with a specific weight:  
i. 0 if the item is absent,  
ii. 1 if it is mild, 
iii. 2 if it is moderate, and 
iv. 3 if it is severe. 
Fibrinoid necrosis and cellular crescents are weighted by a factor of two. The maximum score 
for activity is 24, and the maximum score for chronicity is 12. 
The activity and chronicity scores are widely used as an adjunct to the WHO or ISN/RPS 
classification of LN, even though concerns about their reproducibility and predictability have 
been raised [182]. High scores of renal activity and chronicity according these indices have 
been associated with unfavourable renal prognosis [180, 183].   
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Figure 1.4. Light micrographs of lupus nephritis 
Light micrographs depicting lupus nephritis ISN/RPS class II (upper left: periodic acid-Schiff 
stain; upper right: Ladewig stain), ISN/RPS class IV-G (A) (middle left: haematoxylin and 
eosin stain; middle right: Ladewig stain), ISN/RPS class III (A) (lower left: haematoxylin and 
eosin stain), and ISN/RPS class V (lower right: silver stain). 
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Table 1.6. Renal pathology scoring system for activity and chronicity 
Activity Index Chronicity Index 
Glomerular abnormalities 
1. Cellular proliferation 
2. Fibrinoid necrosis or karyorrhexis 
3. Cellular crescents 
4. Hyaline thrombi or wire loops 
5. Leucocyte infiltration 
Glomerular abnormalities 
1. Glomerular sclerosis 
2. Fibrous crescents 
Tubulointerstitial abnormalities 
1. Mononuclear cell infiltration 
Tubulointerstitial abnormalities 
1. Interstitial fibrosis 
2. Tubular atrophy 
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1.5 MONITORING DISEASE ACTIVITY AND DAMAGE 
 
1.5.1 Evaluation of global SLE disease activity 
 
A large variety of assessment tools is available for monitoring SLE disease activity, as well 
as the response to drug therapy. These tools are based on a range of components, including 
general measures of immunologic and inflammatory status, specific monitoring methods of 
the organs and tissues that are involved, global assessments of disease activity both by 
physicians and patients, as well as general and SLE-specific quality of life measures.   
SLE Disease Activity Index (SLEDAI) was introduced and validated in 1985, and is the most 
commonly used SLE-specific disease activity measure [184]. Based on the presence of 24 
features in nine organ systems, SLEDAI measures disease activity at the time of the 
assessment, and within 10 days preceding the assessment. SLEDAI 2000 (SLEDAI-2K), a 
revised version of SLEDAI, was introduced in 2002 [185]. In SLEDAI-2K, persistent 
ongoing activity in specific items (rash, alopecia, mucosal ulcers, and proteinuria) is scored, 
in contrast to only new occurrences in the original SLEDAI. 
A widely used modification of the SLEDAI is the Safety of Estrogens in Lupus 
Erythematosus National Assessment (SELENA)-SLEDAI. This version of SLEDAI uses the 
same scoring system as the original SLEDAI, but adds clarity to several definitions of activity 
in the individual descriptors [186]. 
The modified SLEDAI-2K (mSLEDAI-2K) is a variant of the SLEDAI-2K in which the 
serologic items (anti-dsDNA and complement levels) are suppressed [187], commonly used 
to assess the clinical disease activity, e.g. when results from serologic tests are not available.   
The systemic lupus activity measure (SLAM) is another index developed to measure global 
SLE disease activity. In order to improve its clarity and reproducibility, a modified version of 
SLAM was introduced in 1992 and was designated the name SLAM-revised (SLAM-R). The 
SLAM-R has received broad acceptance and has been used in numerous studies [188, 189]. 
The European consensus lupus activity measurement (ECLAM) was developed in 1992 [190-
192], and was later validated for use in childhood-onset SLE [193]. However, the ECLAM 
has not been widely used in studies to date. 
The British Isles Lupus Assessment Group (BILAG) index is another commonly used SLE-
specific disease activity measure [194], especially in clinical trials. In the BILAG scale, eight 
organ systems are evaluated and weighted based on disease severity. Within each one of 
these organ domains, multiple laboratory tests and clinical manifestations are combined into a 
single score. The scoring scale in the BILAG index is based on letters, and ranges from A to 
E, A indicating maximal disease activity and E indicating no prior involvement of the organ 
domain. 
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The physician's global assessment (PGA) is most commonly measured on 100 mm visual 
analogue scales (VAS) [186], or according to the SELENA-SLEDAI PGA on a scale 0–3 
[195]. 
 
1.5.2 Evaluation of damage in SLE 
 
The SLICC/ACR damage index (SDI) [196] is the most commonly used index for the 
assessment of irreversible organ damage.  
 
1.5.3 Evaluation of quality of life 
 
Many indices are used for the evaluation of quality of life (QoL). Most of them are neither 
SLE-specific nor thoroughly validated for SLE. Patient reports for pain, fatigue and general 
health on 100 mm VAS are commonly used. Global health is often determined using the 
EuroQoL Research Foundation [197] 5 Dimension (EQ-5D) health questionnaire, which is 
most commonly scored according to the UK tariff [198]. For the assessment of functional 
status, the Stanford Health Assessment Questionnaire (HAQ) functional disability index 
[199] is the most commonly used measure. 
 
1.5.4 Evaluation of treatment response in SLE 
 
The SLE responder index (SRI) was created for use in studies of belimumab [200-202], with 
the aim of meeting guidelines by the FDA and the European Medicines Agency (EMA) for 
evaluating drug therapies in SLE [203]. The SRI was designed to detect overall changes in 
disease activity. According to the SRI, response to treatment is defined as  
i. a reduction of at least four points in the SELENA-SLEDAI score,  
ii. no new BILAG A and no >1 new BILAG B, and  
iii. no worsening in the PGA VAS by ≥30/100 mm, as compared to baseline. 
It is worth nothing that response to treatment according to the SRI is only achieved when all 
three aforementioned criteria are met.  
Another composite index for treatment response is the BILAG-based combined lupus 
assessment (BICLA), first used in a phase IIb randomised control trial assessing the efficacy 
of the anti-CD22 monoclonal antibody epratuzumab in patients with SLE [204]. In BICLA, 
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assessment of irreversible organ damage.  
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EuroQoL Research Foundation [197] 5 Dimension (EQ-5D) health questionnaire, which is 
most commonly scored according to the UK tariff [198]. For the assessment of functional 
status, the Stanford Health Assessment Questionnaire (HAQ) functional disability index 
[199] is the most commonly used measure. 
 
1.5.4 Evaluation of treatment response in SLE 
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ii. no new BILAG A and no >1 new BILAG B, and  
iii. no worsening in the PGA VAS by ≥30/100 mm, as compared to baseline. 
It is worth nothing that response to treatment according to the SRI is only achieved when all 
three aforementioned criteria are met.  
Another composite index for treatment response is the BILAG-based combined lupus 
assessment (BICLA), first used in a phase IIb randomised control trial assessing the efficacy 
of the anti-CD22 monoclonal antibody epratuzumab in patients with SLE [204]. In BICLA, 
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the treatment efficacy is determined by response criteria based on the BILAG-2004 index, a 
revised version of BILAG [205], SLEDAI-2K and PGA. In order to be classified as a 
responder to treatment according to BICLA, the patient has to meet the following 
requirements:  
i. BILAG-2004 index improvement for all A and B scores,  
ii. no >1 new BILAG B,  
iii. no worsening in the SLEDAI-2K score compared to baseline, and 
iv. no >10% worsening in the PGA on a 100 mm VAS. 
The SELENA flare index (SFI) was developed for use in clinical trials to facilitate the 
determination of flares [186, 206, 207].  
 
1.5.5 Evaluation of treatment response in LN 
 
Several definitions of response to induction treatment for LN have been proposed. However, 
to date there is no consensus among researchers regarding which set of criteria should be used 
in clinical trials. The common denominator in all suggested definitions is the requirement of 
reduced proteinuria levels compared to levels prior to treatment initiation. In addition to this, 
measures of renal function and other urinary findings are also included.  
According to the ACR response criteria for proliferative and membranous renal disease in 
SLE clinical trials [208], clinical response to treatment is defined as 
i. at least 50% reduction in proteinuria resulting in levels ≤2 g/day, 
ii. normal estimated glomerular filtration rate (eGFR), defined as >90 mL/min/1.73 m2, 
or, if abnormal at baseline, improved eGFR by ≥25%, and 
iii. inactive urinary sediment, defined as ≤5 red blood cells/high power field, ≤5 white 
blood cells/high power field and no cellular casts.  
Patients who meet these three criteria may additionally be divided into complete and partial 
responders, based on their post-treatment proteinuria level. Complete responders are required 
to have a level of proteinuria below 0.2 g/day, whereas partial response requires proteinuria 
levels between 0.2 g/day and 2 g/day. 
In the more recent European consensus statement on the terminology used in the management 
of lupus glomerulonephritis [167], clinical responders are required to fulfil three conditions: 
i. a proteinuria level of ≤0.2 g/day for complete response and ≤0.5 g/day for partial 
response, 
ii. normal glomerular filtration rate (GFR), defined as >90 mL/min/1.73 m2, or, if 
abnormal at baseline, stable GFR (<10% worsening) for partial response and within 
10% of the normal value for complete response, and  
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iii. inactive urinary sediment, defined as ≤5 red blood cells/high power field, ≤5 white 
blood cells/high power field and no cellular casts. 
According to the same statement, a sustained response of at least three months can be 
regarded as a remission, but an inactive renal biopsy is required in order to consider it a 
complete remission.  
According to the joint recommendations by the European League Against Rheumatism 
(EULAR), the European Renal Association (ERA) and the European Dialysis and Transplant 
Association (EDTA) for the management of adult and paediatric LN [168], complete renal 
response is defined as  
i. a urinary protein to creatinine ratio of <50 mg/mmol, equivalent to an approximate 
proteinuria level of <0.5 g/day, and  
ii. a normal GFR, or, if previously abnormal, a GFR within 10% of the normal value. 
Partial renal response is defined as  
i. a ≥50% reduction in proteinuria to subnephrotic levels, and  
ii. a normal GFR, or, if previously abnormal, a GFR within 10% of the normal value. 
Finally, an exercise initiated by the SLICC group resulted in 2008 in the development of a 
renal activity score and the proposal of a renal response index [209]. The SLICC renal 
activity score ranges from 0 to 15 points, according to the following index: 
i. Proteinuria level 0.5–1 g/day: 3 points 
ii. Proteinuria level >1 g/day but ≤3 g/day: 5 points 
iii. Proteinuria level >3 g/day: 11 points 
iv. Urine red blood cell count >10 cells/high power field: 3 points 
v. Urine white blood cell count >10 cells/high power filed: 1 point 
The SLICC renal response index was based on the following principles:  
i. Complete response is attained if the baseline activity score is greater than 0 and the 
follow-up score equal to 0. 
ii. Partial response is attained if the baseline activity score is greater than the follow-up 
score, but the follow-up score is not equal to 0. 
iii. The renal activity is considered stable if the follow-up activity score is equal to the 
baseline score.  
iv. The renal activity is considered worsened if the follow-up activity score is greater 
than the baseline score. 
However, the SLICC renal activity score and response index have, to date, not been validated 
or used in clinical trials since their development.  
 
27 
iii. inactive urinary sediment, defined as ≤5 red blood cells/high power field, ≤5 white 
blood cells/high power field and no cellular casts. 
According to the same statement, a sustained response of at least three months can be 
regarded as a remission, but an inactive renal biopsy is required in order to consider it a 
complete remission.  
According to the joint recommendations by the European League Against Rheumatism 
(EULAR), the European Renal Association (ERA) and the European Dialysis and Transplant 
Association (EDTA) for the management of adult and paediatric LN [168], complete renal 
response is defined as  
i. a urinary protein to creatinine ratio of <50 mg/mmol, equivalent to an approximate 
proteinuria level of <0.5 g/day, and  
ii. a normal GFR, or, if previously abnormal, a GFR within 10% of the normal value. 
Partial renal response is defined as  
i. a ≥50% reduction in proteinuria to subnephrotic levels, and  
ii. a normal GFR, or, if previously abnormal, a GFR within 10% of the normal value. 
Finally, an exercise initiated by the SLICC group resulted in 2008 in the development of a 
renal activity score and the proposal of a renal response index [209]. The SLICC renal 
activity score ranges from 0 to 15 points, according to the following index: 
i. Proteinuria level 0.5–1 g/day: 3 points 
ii. Proteinuria level >1 g/day but ≤3 g/day: 5 points 
iii. Proteinuria level >3 g/day: 11 points 
iv. Urine red blood cell count >10 cells/high power field: 3 points 
v. Urine white blood cell count >10 cells/high power filed: 1 point 
The SLICC renal response index was based on the following principles:  
i. Complete response is attained if the baseline activity score is greater than 0 and the 
follow-up score equal to 0. 
ii. Partial response is attained if the baseline activity score is greater than the follow-up 
score, but the follow-up score is not equal to 0. 
iii. The renal activity is considered stable if the follow-up activity score is equal to the 
baseline score.  
iv. The renal activity is considered worsened if the follow-up activity score is greater 
than the baseline score. 
However, the SLICC renal activity score and response index have, to date, not been validated 
or used in clinical trials since their development.  
 28 
Different primary and secondary endpoints, different definitions of treatment response, and 
different time points from baseline for the evaluation of the treatment outcome have been 
used in clinical trials of LN. Examples of outcomes that have been utilised include  
i. the progression to ESRD [210],  
ii. the doubling of serum creatinine [211],  
iii. treatment failure defined as an absence of response after six months of therapy, a 
doubling of the serum creatinine, or an incidence of a glucocorticoid-resistant flare 
[212],  
iv. complete remission defined as the attainment of serum creatinine, proteinuria, and 
urinary sediment values within 10% of the ones regarded as normal [213],  
v. improvements in the UPCR and in serum creatinine levels [214], and  
vi. renal response based on serum creatinine, urinary sediment, and UPCR levels [215].  
Again, the common denominator in most of these studies has been the utilisation of 
proteinuria levels and renal function in the endpoints. Importantly, it has been highlighted 
that the choice of definition of treatment response can determine the outcome of a trial and 
whether the trial outcome is interpreted as a success or a failure. The results of a large trial of 
the T cell co-stimulation inhibitor abatacept in SLE constitute an evident example [216]. 
Another aspect that has been discussed is the often worrisomely low degree of agreement 
between physicians in rating the response to treatment in LN using specific definitions [217], 
which also might have a negative impact on the outcome of clinical trials.  
The rate of flares has been used as a treatment outcome in several studies, in particular in 
studies investigating maintenance therapy strategies. Renal flares are common and constitute 
an important feature of the natural history of LN. Although current immunosuppressive 
agents result in adequate clinical responses in the majority of the patients with proliferative 
LN, substantial proportions of the patients, ranging from 27% to 66% in different studies, 
experience one or more flares [218]. However, the introduction and increasing use of 
appropriate long-term maintenance therapies following induction treatment is believed to lead 
to decreases in not only renal, but also extra-renal flare rates in patients with SLE [219]. In 
two large trials comparing the efficacy of azathioprine with that of mycophenolate mofetil 
used as long-term maintenance LN therapies, the rates of renal flares indeed were decreased, 
not exceeding 36% [220, 221]. 
The rather limited incidence rates of LN have been a challenge for clinical trial investigators. 
This limitation becomes more prominent when the distinct morphological characteristics in 
proliferative versus membranous LN and, consequently, the need to investigate these two 
conditions separately are taken into consideration. In a study of pure membranous LN, 
complete remission was defined as a proteinuria level of <0.3 g/day, whereas partial 
remission was defined as a 50% reduction in proteinuria compared to baseline values, 
resulting in a level of <3.5 g/day [222]. In another study of membranous LN, similar 
definitions of complete and partial remission were utilised, yet the reduction of proteinuria 
was required to result in levels below 2 g/day to signify partial remission [223]. 
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Assessing the long-term renal outcome has also been challenging. Here, the common 
denominator in most studies has been the development of ESRD. However, the doubling of 
serum creatinine, chronic renal insufficiency and death have also been used [62, 224-227]. 
To date, there are no broadly used or accepted definitions of histological response to 
induction treatment for LN. An obvious reason is the lack of follow-up renal biopsies at the 
time of the treatment evaluation. However, the importance of histology in the evaluation of 
the treatment outcome has been shown in studies [156, 171, 172] and highlighted in the 
European consensus statement on the terminology used in the management of lupus 
glomerulonephritis [167] and in a recent dialogue [228]. In studies from our group where 
post-treatment renal biopsies were available, we have utilised the Activity Index [181] and 
the 2003 ISN/RPS classification of LN [176], and proposed that complete histological 
response should require 
i. an improvement of ≥50% in the Activity Index score compared to baseline, and 
ii. absence of active lesions in the post-treatment renal biopsy: ISN/RPS class I, II, III 
(C), or IV-S/G (C). 
Partial histological response still required an improvement of ≥50% in the Activity Index 
score compared to baseline, but allowed residual active lesions or a residual membranous 
pattern in the post-treatment renal biopsy: ISN/RPS class III (A), III (A/C), IV-S/G (A), IV-
S/G (A/C), or V [171, 229]. 
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1.6 ANTIPHOSPHOLIPID ANTIBODIES IN SLE AND LN 
  
As previously mentioned, pronounced autoantibody production is one of the consequences of 
the hyperactive B cell lineage in SLE. Antiphospholipid antibodies (aPL) constitute a 
heterogeneous family of antibodies directed against phospholipids or phospholipid-binding 
protein structures. These autoantibodies may be seen in autoimmune diseases, transiently 
during infections, and sometimes even in healthy individuals. The presence of aPL is 
associated with an enhanced risk of thrombotic manifestations in the arterial, venous and 
capillary circulation, as well as with pregnancy complications [230-232]. Among individuals 
with aPL, a fraction develops the antiphospholipid syndrome (APS) and other remain 
asymptomatic carriers [233, 234]. APS may occur as an isolated primary syndrome or a 
secondary condition to an underlying disease, the most common being SLE [235].  
Clinical manifestations of APS include vascular thrombosis in any vessel and in any tissue or 
organ, as well as pregnancy morbidity defined as  
i. one or more unexplained deaths of a morphologically normal foetus at or beyond the 
10th week of gestation, 
ii. one or more premature births of a morphologically normal neonate before the 34th 
week of gestation due to eclampsia, severe preeclampsia [232] or placental 
insufficiency, or  
iii. three or more consecutive unexplained spontaneous abortions before the 10th week of 
gestation, after exclusion of maternal anatomic or hormonal abnormalities and 
paternal or maternal chromosomal anomalies.  
Laboratory findings consistent with APS include  
i. lupus anticoagulant (LA) detected in plasma according to the guidelines of the 
International Society on Thrombosis and Haemostasis [236, 237] on two or more 
occasions at least 12 weeks apart,  
ii. anticardiolipin antibodies (aCL) of IgG and/or IgM isotype in serum or plasma, 
present in medium or high titres (>40 IgG or IgM phospholipid units, or >the 99th 
percentile), on two or more occasions at least 12 weeks apart, measured by a 
standardised enzyme-linked immunosorbent assay (ELISA) [238-240], and  
iii. anti-β2-glycoprotein-I antibodies (anti-β2-GPI) of IgG and/or IgM isotype in serum or 
plasma (in a titre of >the 99th percentile), present on two or more occasions at least 12 
weeks apart, measured by a standardised ELISA [241].  
For classification of definite APS, at least one of the clinical manifestations and at least one 
of the laboratory aforementioned findings have to be met [230]. In clinical praxis, aPL testing 
is also performed in order to identify risk factors for thrombotic events and pregnancy 
complications in specific patient groups rather than to diagnose the syndrome [242, 243].  
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Renal artery and vein thrombosis, renal infarction, and thrombotic microangiopathy (TMA) 
are several of the renal manifestations that have been associated with aPL [244]. Coexistence 
of aPL and intrarenal vascular changes, such as TMA, fibrous intimal hyperplasia and focal 
cortical atrophy, constitute a condition called aPL-associated nephropathy (APLN) [230]. 
Histological findings consistent with APLN have been termed APS nephropathy (APSN) 
[245, 246], and studies have shown that APSN may occur in a limited fraction of SLE 
patients without antiphospholipid antibodies [247, 248]. Vascular lesions consistent with 
APLN may be present in renal biopsies from patients with LN [246, 248-250], and have been 
demonstrated to be associated with the development of ESRD [248]. 
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1.7 BIOMARKERS 
 
According to the National Institute of Health (NIH) Biomarkers Definitions Working Group, 
a biomarker is "a characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention" [251]. Biomarkers may include genetic, biologic, biochemical, molecular, and 
imaging tests. An ideal biomarker should sensitively and accurately respond to changes in 
disease state, as well as should be relevant to the pathophysiological condition that it is 
supposed to reflect or predict, minimally invasive, simple to measure and interpret, and cost-
effective. Finally, a biomarker should not be affected by comorbid conditions.  
Today, the diagnosis of SLE relies upon clinical features and laboratory tests. The 
classification criteria used in clinical trials and in basic science investigations to warrant 
homogeneity in the selection of participating patients have limitations when used in clinical 
practice [22]. While ANA are highly sensitive but not specific as diagnostic markers of SLE 
[22, 252], anti-dsDNA and anti-Sm display high specificity but poor sensitivity [253, 254]. 
Antibodies such as anti-SSA, anti-SSB and anti-RNP are used in the evaluation of SLE, but 
they are not reliable in distinguishing SLE from other autoimmune diseases. Further, the 
methodologies for autoantibody measurements are not standardised.  
Apart from the need of diagnostic biomarkers, reliable biomarkers for measuring disease 
activity are also lacking. Anti-dsDNA, C3, and C4 are widely used for this purpose and are 
incorporated in disease activity indices. However, while they may be useful in individual 
patients, they are inconsistent in others.  
The molecules investigated as potential biomarkers in Paper II and Paper III in this thesis 
and their rationale in the context of SLE and LN are discussed in detail below.  
 
1.7.1 The role of TNFR2 in LN 
 
Tumour necrosis factor α (TNF-α) is a multifunctional cytokine with a pivotal role not only in 
immune responses, such as the defense against viral, bacterial and parasitic infections, but 
also in autoimmunity [255]. The biological functions of TNF-α are mediated through binding 
to two cell surface receptors: 
i. TNF receptor 1 (TNFR1), also known as TNFRSF1A, CD120a, and p55, and  
ii. TNF receptor 2 (TNFR2), also known as TNFRSF1B, CD120b, and p75 [256]. 
Although TNFR1 and TNFR2 are strongly correlated to each other, they have distinct roles in 
immune responses, apoptosis, and inflammatory renal injury [257, 258]. In general, an 
exclusive TNFR1 signal triggers cascades that may result in apoptosis, depending on the cell 
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i. TNF receptor 1 (TNFR1), also known as TNFRSF1A, CD120a, and p55, and  
ii. TNF receptor 2 (TNFR2), also known as TNFRSF1B, CD120b, and p75 [256]. 
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exclusive TNFR1 signal triggers cascades that may result in apoptosis, depending on the cell 
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type, the activation state of the cell, and the cell cycle. By contrast, exclusive TNFR2 
signalling induces cell survival pathways resulting in cell proliferation, especially in activated 
T cells. However, protein defects in the TNFR2 signalling pathway in autoreactive T cells 
may result in the TNFR2 signal preferentially using the TNFR1 pathway, leading to selective 
apoptosis [259]. 
Accumulating evidence indicates the involvement of TNFRs in kidney diseases [257, 260-
265], and in SLE [266-276]. In patients with diabetes, high soluble (s)TNFR levels predicted 
progression of chronic kidney disease (CKD) and development of ESRD [260, 261], and 
were associated with progression of albuminuria [264] and renal function deterioration [263]. 
In other cohorts, sTNFR levels correlated with renal function and albuminuria even in the 
absence of diabetes [262]. In IgA nephropathy, elevated sTNFR levels were associated with 
the severity of renal interstitial fibrosis [265]. Moreover, high sTNFR levels at the time of the 
initial diagnosis of idiopathic membranous nephropathy were predictive of poor renal 
outcome [277].  
There is evidence of TNFR2 expression on cells within specific lymphocyte populations, 
including T regulatory cells (Tregs) [278, 279], as well as on human bone marrow-derived 
mesenchymal stem cells [280] and cardiac myocytes [281]. Mechanistically, TNFR2 has 
been shown to be important in the regulation of apoptotic cell death [282], the proliferation of 
thymocytes and cytotoxic T cells [283, 284], the initiation of cutaneous immune responses 
[285], and the proliferation and protection of collagen [286]. In the CNS, TNFR2 is 
expressed on specific neuron subtypes [287], on microglia and on endothelial cells [288], and 
contributes to the protection of microglia from TNF-induced injuries [289] and to the 
regeneration of oligodendrocytes after demyelination [290]. Soluble TNFR2 is the circulating 
form of TNFR2, formed by proteolytic cleavage of its membrane-bound counterpart. In 
recent years, sTNFR2 has been suggested as a candidate biomarker in several conditions, e.g. 
specific types of heart failure [291], multiple sclerosis [292] and B cell lymphoma [293]. 
Genetic loci associated with SLE include loci encoding TNFR2 [275], and experiments have 
demonstrated associations of TNFR2 polymorphisms with SLE [267, 268, 271]. Levels of 
sTNFR2 have been shown to be higher in patients with SLE than in healthy controls [266, 
270], as well as during active SLE disease or prior to flare than during inactive disease [266, 
272], and they have also been shown to correlate with SLE disease activity, renal 
involvement, and cardiovascular comorbidities [270, 273, 274].  
In LN, sTNFR2 levels have been shown to be elevated prior to treatment and decreased six 
months after treatment [266]. In recent reports, sTNFR2 levels were able to differentiate 
patients with active LN from patients with active non-renal or inactive SLE [294], and 
correlated strongly with renal function, as well as with activity and chronicity features in 
renal biopsies [295]. 
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1.7.2 The role of BLyS and APRIL in LN 
 
Considering the role of B cells in the pathogenesis of SLE, B cell activating cytokines have 
recently received increasing attention not only as candidate biomarkers, but also as target 
molecules for the development of new therapies. B lymphocyte stimulator (BLyS), also 
known as B cell activating factor belonging to the TNF family (BAFF), THANK, TALL-1 
and zTNF4, is a member of the TNF ligand superfamily (TNFSF13B), known for its role in 
the activation, differentiation and survival of B cells [296, 297]. BLyS is constitutively 
produced in stromal cells within lymphoid organs [298], but it is also expressed as a 
transmembrane protein on lymphocytes and various cell types of myeloid origin, including 
monocytes, dendritic cells, macrophages, neutrophils and osteoclasts [299-302]. The 
membrane-bound form can then be cleaved from the cell surfaces to generate a soluble 
fragment. This soluble form of BLyS may appear in the periphery as a single protein, as a 
homotrimer, or in heterotrimer formations together with a proliferation-inducing ligand 
(APRIL). BLyS binds to at least three TNF receptor superfamily members:  
i. BAFF receptor (BAFF-R), also known as BLyS receptor 3 (BR3),  
ii. B cell maturation antigen (BCMA), and  
iii. transmembrane activator and calcium modulator and cyclophilin ligand interactor 
(TACI) [303-305] (Figure 1.5).  
BLyS-deficient mice have been shown to lack mature B cells [306]. In other murine settings, 
selective BLyS blockade has been demonstrated to prevent the development of 
glomerulonephritis [126], whereas overexpression of BLyS in transgenic mice initiated the 
expansion of the mature B cell compartment resulting in lupus-like autoimmune 
manifestations, such as nephritis and arthritis [307]. In human studies, patients with SLE and 
other autoimmune diseases, e.g. rheumatoid arthritis, have been shown to overexpress BLyS 
[308-311], and circulating BLyS levels have been shown to correlate with SLE disease 
activity and concentrations of autoantibodies [311, 312]. Further, SLE patients with renal 
involvement have been demonstrated to have higher levels of serum BLyS compared to non-
renal SLE patients [313]. Another study found higher levels of BLyS mRNA in glomeruli 
from patients with proliferative LN than in control tissue from pre-transplant biopsies from 
living donors [314], indicating a role of BLyS in this LN subset.  
APRIL is another member of the TNF ligand superfamily (TNFSF13), involved in the 
induction and maintenance of B cell and T cell responses [315]. APRIL is produced by cells 
of the myeloid lineage, with a discernible peak in myeloid precursor cells [316]. Like BLyS, 
APRIL binds to BCMA and TACI. However, is does not bind to BAFF-R (Figure 1.5). In 
SLE, monocytes and dendritic cells have been demonstrated to express CD138, and trans-
present CD138-bound APRIL to B lymphocytes promoting IgA responses [317]. CD138 
expressed on plasma cells has been described as an APRIL-binding partner, being the 
prerequisite for the triggering of TACI- and/or BCMA-mediated plasma cell survival [318]. 
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CD138-bound APRIL on the surface of plasma cells can create unique niches that support the 
accumulation of plasma cells and local antibody production [319]. 
In murine models, it has been demonstrated that overexpression of APRIL leads to increased 
frequencies of B lymphocytes and serum IgM levels [302]. Contrary to BLyS-deficient mice, 
APRIL-deficient ones had normal B lymphocyte populations in the periphery [302]. Several 
studies have demonstrated elevated serum levels of APRIL in patients with SLE [311, 320, 
321], whereas in other reports, levels of APRIL did not differ from values regarded as normal 
[322]. Further, APRIL levels have been demonstrated to be lower in SLE patients with renal 
disorder compared to non-renal SLE patients [313], and levels of APRIL mRNA have been 
shown to be higher in the glomeruli of proliferative LN patients compared to tissue from 
living donors [314].  
A direct interplay between myeloid dendritic cells and B cells has been implicated in the 
pathogenesis of SLE. Monocyte differentiation into dendritic cells has been shown to be 
induced in a type I IFN-dependent manner [323]. A study demonstrated that SLE dendritic 
cells efficiently stimulate naïve and memory B lymphocytes to differentiate into IgG and IgA 
plasmablasts resembling those in the peripheral blood of SLE patients. This dendritic cell-
mediated differentiation into IgG plasmablasts was then found to be dependent on BLyS and 
IL-10, and the respective differentiation into IgA plasmablasts was dependent on APRIL. It is 
worth noting that dendritic cells in SLE express CD138 and trans-present CD138-bound 
APRIL to B lymphocytes, resulting in the induction of IgA switching and plasmablast 
differentiation independently of IFN-α [317]. Collectively, it is not surprising that BLyS and 
APRIL have been studied as candidate targets for drug therapy in SLE. 
 
 
Figure 1.5. BLyS and APRIL, and their receptors on the B cell surface 
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1.8 PHARMACOTHERAPY IN SLE 
 
1.8.1 General management 
 
Systemic lupus erythematosus has historically been managed non-specifically, with 
symptomatic treatments. The reason for this can be traced to  
i. the lack of therapies targeting specific immune components, with the possible 
exceptions of belimumab, rituximab and cyclosporine, and  
ii. the wide spectrum of clinical manifestations.  
Thus, the treatment strategies of SLE vary and are individual, depending on the organ 
involvement, the severity of the disease and the complications. The treatment of non-major 
organ involvement includes glucocorticoids, antimalarial agents, and NSAIDs. In severe 
cases, or in patients in whom no response to treatment is achieved, azathioprine, 
mycophenolate mofetil and methotrexate are commonly used. Despite their widespread use, 
only a limited fraction of these drugs or drug classes has received approval by drug agencies 
for the treatment of SLE. Antimalarial agents, acetylsalicylic acid, and glucocorticoids had, 
for many years, and until recently, been the only drugs approved for SLE. 
The wide variety of beneficial effects that are associated with the use of antimalarial agents in 
SLE makes this drug class the cornerstone of SLE therapy [324, 325]. The modulatory effects 
of antimalarial agents on immune responses are mediated by several mechanisms, one of 
them being the interference with antigen processing. The use of this drug class in SLE has 
been associated with remission maintenance effects [324], and, importantly, it has been 
shown to prevent flares and decrease the corticosteroid use during pregnancy [326]. 
Moreover, hydroxychloroquine has been shown to be associated with improved renal 
prognosis in patients with LN [327], and based on their atheroprotective effects, antimalarial 
agents are expected to be beneficial in SLE patients at high risk for thrombotic events, e.g. 
patients with APS or high titres of aPL.  
Glucocorticoids have rapid and powerful anti-inflammatory and immunosuppressant effects 
[328], and are used for most SLE manifestations, from mild cutaneous disease to life-
threatening conditions, often in combination with other drugs. Pulse methylprednisolone 
therapy is commonly used during severe exacerbations to induce remission, followed by high 
doses of oral corticosteroids, e.g. prednisone, with a gradual taper. Low-dose oral 
corticosteroids are used in the vast majority of SLE patients as a long-term remission 
maintenance therapy. However, the glucocorticoid-induced harm, including cushingoid 
adverse effects, osteoporosis and cataracts, especially in cases of long-term use, has in recent 
years received increasing recognition. Apart from complications, recent indications of 
harmful effects of glucocorticoids on SLE itself have contributed to scepticism towards the 
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current acceptance among physicians regarding the inevitability of long-term glucocorticoid 
use, and a need for a paradigm shift has been implied [329]. 
Moderate to severe flares in major organs are usually managed with an initial induction 
therapy using methylprednisolone, cyclophosphamide, mycophenolate mofetil, or 
combinations thereof [330-332]. In LN, the low-dose regimen proposed in the Euro-Lupus 
Nephritis Trial [212] is the most commonly used cyclophosphamide regimen, and comprises 
pulses of 0.5 g cyclophosphamide, one every second week for a total of three months, 
followed by maintenance therapy with azathioprine. Together with mycophenolate mofetil, 
they have in the current management of LN replaced the initial cyclophosphamide regimen of 
monthly intravenous pulses of 0.75–1.5 g/m2 according to the NIH protocol [210, 211, 333], 
mainly because of severe infections and toxicity concerns, e.g. associations with premature 
gonadal failure [334]. In patients with LN who have not responded to this management, the 
anti-CD20 monoclonal antibody rituximab, further discussed in chapter 1.8.2, may be an 
alternative [129]. 
The prospect of calcineurin inhibitors as potential therapeutic agents in SLE, especially LN, 
has received growing attention [335]. Low doses of tacrolimus have been demonstrated to be 
effective and well tolerated in LN patients who had failed treatment with cyclophosphamide 
[336], and an open-label prospective study showed non-inferiority of tacrolimus as an 
induction therapy of active biopsy-proven LN compared to mycophenolate mofetil and 
cyclophosphamide [337]. Later, a meta-analysis of a total of nine studies demonstrated that 
tacrolimus was superior to cyclophosphamide, but not to mycophenolate mofetil, in inducing 
complete renal remission in LN [338].  
As pharmacological research develops, more targeted therapies have been suggested and 
investigated. Biological agents have been used, mostly during the last decade, either 
following approval or as off-label therapies. Several of them are discussed in chapter 1.8.2. 
Future strategies that may prove promising include small molecules modifying intracellular 
signal pathways, e.g. through targeting Lyn, Syk, PI3Ks and Btk, as mentioned in chapter 1.3.  
The proteasome inhibitor bortezomib, approved for the treatment of multiple myeloma, was 
recently shown to improve the disease activity and reduce the numbers of peripheral blood 
and bone marrow plasma cells in twelve refractory SLE patients [339]. 
 
1.8.2 Biologics in SLE 
 
Biologic agents have, in recent years, been the focus of research towards the development of 
modern therapies (Figure 1.6). Due to its important role in B cell homeostasis, BLyS has been 
of central interest as a target molecule. 
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Belimumab is the first drug to be licensed for use in SLE in more than fifty years, and the 
first biologic agent approved for the disease. The efficacy of belimumab, previously known 
as Lympho-Stat B, in reducing SLE activity has been shown in two large, phase III, 
randomised, placebo-controlled clinical trials [201, 202], with serologically active patients 
showing better responses [340]. This resulted in the approval of belimumab as a treatment for 
patients with moderately active SLE despite ongoing standard of care therapy.  
Belimumab is a recombinant human IgG1-λ monoclonal antibody that specifically binds to 
the soluble form of BLyS, and thus prevents the binding of BLyS to its receptors on the 
surface of B cells. Normally, the binding of BLyS to B cells prolongs their survival and 
promotes their maturation and differentiation towards immunoglobulin and autoantibody 
production [297]. BLyS signalling also leads to increases in anti-apoptotic proteins. As 
defective clearance of apoptotic cells is implicated in the pathogenesis of SLE and the 
stimulation of autoantibody production, the reductions in anti-apoptotic proteins as a result of 
BLyS inhibition is expected to hamper this B cell-driven component in the pathogenesis of 
the disease. The trials of belimumab are further described in detail in the sections 18.2.1–10.  
Rituximab is a chimeric anti-CD20 monoclonal antibody, widely used for the treatment of 
non-Hodgkin lymphoma, rheumatoid arthritis, vasculitis and other autoimmune diseases, and 
also, even though not extensively, as an off-label therapy in refractory SLE, mostly therapy-
resistant LN [341, 342]. CD20 is expressed by mature B cells, B cell precursors, and memory 
B cells, but is not found on haematopoietic stem cells, pro-B cells, or terminally differentiated 
plasma cells. Three mechanisms of action have been proposed for the elimination of B cells 
by rituximab: 
i. antibody-dependent cell-mediated cytotoxicity, 
ii. complement-mediated cytotoxicity, and  
iii. stimulation of the apoptotic pathway [343, 344].  
The time to B cell recovery following rituximab treatment varies. In rituximab-treated 
lymphoma patients, B cell depletion has been shown to be rapid and sustained for up to six to 
nine months, whereas normal B cell levels returned by twelve months following completion 
of treatment [345]. In patients with rheumatoid arthritis, B cell depletion has been 
demonstrated to be prolonged with some patients showing B cell recovery two years or 
longer following treatment [346]. 
Several centres have reported uncontrolled experiences with rituximab for the treatment of 
severe and refractory SLE, including LN cohorts [128, 129, 131, 132, 347-354]. Studies of 
refractory renal SLE treated with rituximab combined with cyclophosphamide reported 
beneficial effects on various outcomes [129-133, 355]. However, randomised controlled trials 
(RCTs) of rituximab treatment in patients with SLE failed to show efficacy [215, 356].  
The LN assessment with rituximab (LUNAR) trial comprised 144 patients with proliferative 
glomerulonephritis (WHO class III and IV) [215]. The patients were randomised to receive 
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glomerulonephritis (WHO class III and IV) [215]. The patients were randomised to receive 
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rituximab or placebo in addition to mycophenolate mofetil and high doses of corticosteroids. 
The trial failed to demonstrate superiority of rituximab to placebo. However, the placebo 
group received a treatment which alone has been shown to be efficacious in inducing renal 
remission or low renal activity, being a possible reason for the negative study results [357]. 
A randomised trial with rituximab in non-renal SLE, the exploratory phase II/III SLE 
evaluation of rituximab (EXPLORER) trial, in which rituximab was added to standard of care 
therapy with antimalarial agents, immunosuppressive drugs and corticosteroids, also failed to 
demonstrate beneficial outcomes for rituximab versus placebo [356]. 
Despite the negative results of the RCTs, rituximab has been included in the joint 
EULAR/ERA-EDTA recommendations for LN [168], as well as in the ACR guidelines for 
the management of renal SLE [169]. The drug is widely used in clinical praxis as an off-label 
therapeutic option for refractory renal SLE, as well as for other organ manifestations, such as 
severe arthritis, haematologic abnormalities, and neuropsychiatric SLE when conventional 
therapies have failed [341, 358-360].  
Atacicept is another biologic agent that has been studied as a candidate drug for SLE. Being a 
receptor construct that combines TACI with the Fc portion of human IgG, atacicept blocks 
the effects of both BLyS and APRIL [361]. A clinical trial of atacicept in LN was terminated 
prematurely, due to adverse events, i.e. hypogammaglobulinemia and infections [362]. 
Blisibimod is a fusion protein consisting of four high-affinity BLyS-binding domains and the 
Fc domain of human IgG1, targeting both soluble and membrane-bound BLyS. A dose-
ranging phase IIb clinical trial of blisibimob [363] determined a safe and effective dose to 
further be studied in a phase III trial, which unfortunately failed to meet its primary endpoint. 
Only one of the two phase III RCTs of tabalumab, a fully human monoclonal antibody 
targeting soluble and membrane-bound BLyS, met its primary endpoint [364, 365], and no 
further development of the drug is planned for SLE. However, it is worth noting that no dose-
ranging phase II studies had preceded the phase III RCTs. Several key outcomes in both trials 
still justify the rationale of targeting BLyS in SLE [366, 367].   
Epratuzumab is a humanised monoclonal antibody against CD22, a cell surface antigen found 
on mature B cells. Treatment with epratuzumab has been shown to significantly reduce the 
frequencies of CD22 and CD19 within peripheral blood B cells in SLE patients [368]. Two 
phase II [369] and one phase IIb [204] clinical trials demonstrated favourable effects of 
epratuzumab on SLE disease activity, prompting the initiation of two phase III trials, which 
unfortunately failed to meet their primary clinical efficacy endpoints [370].  
The rationale of blocking IL-6 to treat SLE has been based on studies showing elevated 
serum levels of this cytokine in patients with SLE [371] and increased urinary excretion in 
SLE patients with active nephritis [372]. Experimental inhibition of IL-6 in murine lupus has 
been demonstrated to impede autoreactive B cell activity and ameliorate nephritis features 
[373, 374]. However, a proof-of-concept study of the high‐affinity human anti-IL-6 
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monoclonal antibody sirukumab in patients with active LN failed to demonstrate superiority 
of the drug to placebo when added to concomitant immunosuppressive treatment [375]. A 
phase I trial of the IL-6 receptor antagonist tocilizumab in SLE showed improved disease 
activity and decreased circulating plasma cell counts and autoantibody production. However, 
a concern was the observed dose-related decrease in absolute neutrophil counts [376]. 
The importance of the type I IFN pathway in the pathogenesis of SLE has prompted the 
investigation of anti-IFN antibodies as potential drugs for SLE [377]. Initial reports on 
several different approaches have confirmed biologic effects and revealed tolerability [378-
382]. The first published data supporting the efficacy of INF-α inhibition came from a phase 
IIb RCT of sifalimumab in adult patients with active SLE [383]. The results were modest but 
in favour of sifalimumab. However, a phase II study demonstrated that rontalizumab, another 
monoclonal anti-INF-α antibody, was superior to placebo in patients with low IFN-regulated 
gene expression, but not in patients with high IFN gene signature [384], contrary to what 
expected considering the biologic mechanism of the drug. 
A phase II trial of the type I IFN receptor inhibitor anifrolumab has been successful, meriting 
further development of this new biologic agent. Anifrolumab was more efficacious compared 
to placebo, especially in patients with a high IFN gene signature based on a gene expression 
assay including four genes. However, no dose response could be displayed [385]. Results 
from ongoing phase III trials, as well from an ongoing phase II trial of anifrolumab in LN, are 
eagerly anticipated.  
Another molecule that has been investigated as a potential treatment for SLE is abatacept, a 
soluble fusion protein comprising the extracellular domain of the human cytotoxic T 
lymphocyte-associated protein 4 (CTLA-4) and a fragment of the Fc portion of human IgG1. 
T cell activation relies on co-stimulatory interactions. The interaction of CD80/86 on antigen-
presenting cells with CD28 on T cells is one of the most important co-stimulatory pathways. 
The CLTA-4 molecule is homologous to CD28, but binds to CD80 and CD86 with higher 
affinity, resulting in competitive inhibition of the binding of CD28 to CD80/CD86 and, thus, 
termination of the T cell activation. Abatacept is approved for use in rheumatoid arthritis and 
has also been studied in other autoimmune diseases. Data from animal studies revealed the 
rationale for the use of abatacept in SLE [386], resulting in two RCTs. SLE patients with a 
current mucocutaneous, musculoskeletal or serositis flare were included in the first trial 
[387]. Unfortunately, abatacept did not prove more efficient in preventing flares compared to 
placebo. A concern raised later was whether the choice of the primary endpoint in this trial 
concealed the inferiority of abatacept to placebo [357], e.g. given the highlighted poor 
agreement between physicians on the presence or absence of mild and moderate flares [207]. 
The second trial of abatacept in SLE was a phase II/III RCT comprising 298 patients with 
active biopsy-proven proliferative LN [388]. The patients were randomised to receive 
abatacept or placebo in addition to glucocorticoids and mycophenolate mofetil. The time to 
attain complete response did not differ between the treatment arms, but greater improvements 
were seen in favour of abatacept regarding anti-dsDNA and C3 and C4 levels, as well as 
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proteinuria levels in patients with nephritic-range proteinuria at baseline. Later, a reanalysis 
that used different definitions of renal response unveiled clear inferiority of abatacept to 
placebo [216], highlighting that the choice of outcomes in clinical trials may be critical to 
their success.  
Lupuzor, also known as P140 peptide and IPP-201101, is not a biologic, but a 21-mer linear 
peptide originating from the small nuclear ribonucleoprotein U1-70K, phosphorylated at the 
Ser140 position. Although the mechanism of action of the P140 peptide has not been fully 
elucidated, studies in lupus-prone mice have shown immunomodulatory effects leading to the 
inhibition of T cell reactivity with MHC-presented self-peptides [389-394]. In a phase IIb 
RCT comprising 149 patients with SLE, administration of Lupuzor as an add-on to standard 
of care therapy reduced the SLE disease activity, resulting in greater response rates than in 
the patient group given placebo [395]. 
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1.8.2.1 Clinical trials of belimumab in SLE 
 
Early trials were inconclusive. A phase II trial comprising 449 patients failed to meet its 
primary endpoints [200]. However, a significant fraction of the patients included in the study 
(30%) had no ANA at baseline, and the validity of their diagnosis was later questioned. The 
first successful RCT of belimumab in SLE was the BLISS-52 trial. The study comprised 865 
patients with a moderate to severe SLE and positive immunologic markers. Modest but 
consistent improvements through week 52 were displayed across various clinical outcomes 
[201]. In a second RCT of similar design (BLISS-76) comprising 819 patients, the 
observation period was prolonged to a total of 76 weeks. The primary efficacy endpoint was 
reached at week 52 in patients who received belimumab 10 mg/kg, but the results following 
the 76-week observation period were rather inconclusive [202].  
 
1.8.2.2 Phase II RCT 
 
In the phase II RCT of belimumab, 449 patients with a SELENA-SLEDAI score of ≥4 were 
assigned to receive belimumab 1, 4 or 10 mg/kg, or placebo. Standard of care treatment was 
allowed in all arms. The study was carried out for 52 weeks. The primary endpoints were the 
change in SELENA-SLEDAI at week 24, and the time to the first flare [200]. 
Patients in the belimumab arms achieved a reduction of 19.5% in SELENA-SLEDAI scores 
compared to baseline versus 17.2% in the placebo arm (P=0.68). The median time to the first 
flare was 67 days in the belimumab arms and 83 days in the placebo arm. When only 
serologically active patients were analysed, belimumab treatment reduced the SELENA-
SLEDAI scores by 28.8% versus 14.2% for placebo (P=0.04), it improved the PGA scores by 
32.7% versus 10.7% for placebo (P=0.001), and it increased the SF-36 physical component 
scores by 3.0 versus 1.2 in the placebo arm (P=0.04). Adverse events were equally frequent 
across the different groups. Overall, the trial demonstrated that belimumab was biologically 
active and well tolerated. However, no dose response was observed. 
 
1.8.2.3 BLISS-52 
 
The first BLISS trial comprised 865 adult seropositive SLE patients with SELENA-SLEDAI 
scores of ≥6. The patients were assigned to one of three treatment groups: belimumab 1 
mg/kg, belimumab 10 mg/kg or placebo, as intravenous infusions on days 0, 14 and 28, and 
every 28th day thereafter until week 48. Standard of care therapy was allowed in all arms. The 
primary efficacy endpoint was improvement in the SRI at week 52 [201]. 
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Higher SRI response rates were displayed in both belimumab arms compared to placebo, and 
rates of adverse events did not differ across the three arms [201]. 
 
1.8.2.4 BLISS-76 
 
The BLISS-76 trial had similar design to that of BLISS-52, with the same treatment arms and 
primary endpoint. In this trial, however, the patients (n=819) were followed for 76 weeks 
[202].  
At week 52, the SRI response rate was greater in the belimumab 10 mg/kg arm (43.2%) 
compared to the placebo arm (33.5%) (P=0.017), but the difference between the belimumab 1 
mg/kg arm (40.6%) and the placebo arm did not reach statistical significance (P=0.089). At 
week 76, the SRI response rates in the 10 mg/kg belimumab arm (38.5%) and the 1 mg/kg 
belimumab arm (39.1%) were numerically greater compared to the placebo arm (32.4%), but 
the differences were not statistically significant. As in BLISS-52, adverse event rates were 
comparable across the three arms [202]. 
 
1.8.2.5 Organ-specific effects of belimumab 
 
The RCTs of belimumab were neither designed nor powered to investigate the clinical effects 
on individual organ domains. However, post-hoc analyses with data from both BLISS trials 
demonstrated the effects of belimumab treatment on organ-specific disease activity using 
BILAG and SELENA-SLEDAI [396, 397]. The predominantly represented domains at 
baseline were mucocutaneous, musculoskeletal, and immunologic. The evaluation of 
response rates in patient groups with different manifestations implicated superiority of 
belimumab to placebo not only in the musculoskeletal and mucocutaneous domains, but also 
in immunologic and renal descriptors, and even in items with lower prevalence at baseline, 
e.g. vasculitis and involvement of the CNS [396]. 
 
1.8.2.6 Effects on serologic markers 
 
In both BLISS trials, treatment with belimumab resulted in improvements in serologic 
activity, which were already noted at week eight and sustained until the end of the 
observation period [201, 202]. Normalisation of low complement levels and 
hypergammaglobulinemia was noted in significantly more patients treated with belimumab 
compared to placebo. Greater reductions in anti-dsDNA levels in the belimumab versus the 
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placebo arms were also noted, and the reduction in anti-dsDNA IgG concentrations was 
greater than the reduction in total IgG, implicating selective effects of belimumab on 
autoantibody production [398]. This supported the notion that serologically active SLE 
patients indicating B lymphocyte hyperactivity are more likely to respond belimumab 
treatment, and was consistent with the results of the phase II trial [200], as well as with a 
post-hoc analysis of the BLISS trials showing that patients with positive anti-dsDNA titres 
and low complement levels were more likely to benefit from belimumab [340]. 
The effects of belimumab on autoantibody and Ig levels were further assessed in pooled data 
from the BLISS trials, showing that belimumab treatment in addition to standard of care 
therapy led to sustained reductions in autoantibody levels [399]. Both the low and the high 
dosage groups displayed reductions in multiple B cell and plasma cell subsets, including 
naïve and activated B cells, and CD20+CD138+ plasma cell precursors. The reductions in 
plasma cell subsets displayed indications of dose dependence. Memory B cells and T cell 
populations were preserved [399]. The clinical implications of these findings may be 
important, given the knowledge that SLE disease activity is associated with elevated numbers 
of plasma cell subsets [400]. Furthermore, the preservation of memory B cells observed in the 
RCTs was consistent with previous research findings showing that the survival of memory B 
cells does not rely on BLyS [401]. These findings provide an explanation for the implications 
of maintained immune responses to infections in SLE patients treated with belimumab in the 
three RCTs [20]. 
 
1.8.2.7 Drug interactions 
 
Concurrent administration of corticosteroids, NSAIDs, antimalarial agents, azathioprine, 
methotrexate, mycophenolate mofetil, angiotensin II receptor antagonists, angiotensin-
converting enzyme inhibitors and statins was not found to significantly modify the 
pharmacokinetic properties of belimumab [402]. Patients who had received pneumococcal or 
tetanus vaccines within five years prior to the BLISS-76 trial were shown to maintain their 
antibody levels at week 52 [399]. Moreover, seven out of the seven patients who were 
vaccinated with pneumococcal or tetanus vaccines after commencing treatment with 
belimumab developed protective antibody levels. However, the response to vaccines during 
belimumab treatment has not been sufficiently studied. Considering the mechanism of action 
of belimumab and the expected immunologic effects, one might anticipate diminished 
responses to vaccines.  
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1.8.2.8 Effects of belimumab on corticosteroid usage 
 
Steroid-sparing effects of belimumab were implicated both in the BLISS-52 [201] and the 
BLISS-76 [202] trials. Greater reductions in prednisone doses were noted in the belimumab 
arms compared to placebo in both BLISS trials, but statistical significance was only reached 
during the last 36 weeks in the BLISS-52 trial. 
 
1.8.2.9 Safety profile 
 
The most common adverse events were infections, with similar rates across the groups [20]. 
Hypersensitivity reactions were uncommon and manageable with standard treatment, and 
they were most likely to occur during or following the first two infusions. However, 
premedication was allowed in the trials and was administered based on individual judgment 
by the investigator. Several cases of severe infusion reactions were later noted in real-life use, 
including a few that occurred with a delay of several hours, and one fatal. 
A total of nine malignancies were reported in the three RCTs, seven of them in the BLISS-76 
trial: one solid-organ cancer in the placebo arm, and three solid-organ and three non-
melanoma skin malignancies in the belimumab arms. Two malignancies were reported in the 
phase II trial, one in the belimumab 10 mg/kg arm and one in the placebo arm. Both were 
non-melanoma skin malignancies. The distribution revealed no prevailing pattern or type of 
malignancy across the different groups. Importantly, no haematologic cancers were reported. 
Finally, none of the deaths that were reported was attributed to belimumab [20]. 
 
1.8.2.10 Significance and future perspectives 
 
The results of the trials were modest but consistently favoured belimumab over placebo. 
These trials of SLE are the largest to date; therefore, the methodologies employed have 
important implications for future research in SLE.  
The prospect of subcutaneous administration has been investigated in phase I studies [403], 
as well as in a phase III clinical trial demonstrating favourable clinical outcomes in patients 
who received belimumab 200 mg administered as weekly subcutaneous injections compared 
with patients in the placebo arm [404].  
The fact that patients with active neuropsychiatric SLE and severe LN were excluded from 
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1.8.2.8 Effects of belimumab on corticosteroid usage 
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covering a wider spectrum of SLE manifestations are needed to fully explore the applicability 
of belimumab. Importantly, real-life experiences are eagerly anticipated. 
 
1.8.3 Adjunctive therapies 
 
Low-dose aspirin may be used for primary prevention of thrombosis in SLE patients with 
APS, whereas long-term use of heparin, low-molecular-weight heparin, or warfarin should be 
used for secondary prevention [330, 405]. In patients with LN, the role of global care in 
addition to immunosuppressive treatment is important. The blood pressure should be 
monitored regularly, and angiotensin converting enzyme (ACE) inhibitors and/or angiotensin 
II receptor blockers (ARBs) should be considered in all LN patients.  
Moreover, the follow-up of SLE patients should include risk factors and routine tests for 
cardiovascular comorbidities, e.g. dyslipidaemia or hyperlipidaemia. The patients should 
regularly be monitored for signs of subclinical infections, especially patients with frequent 
events of neutropenia, as well as for osteopenia and osteoporosis, especially patients 
administered long-term and/or high-dose corticosteroid therapy and post-menopausal women. 
Depending on the medication and the clinical situation, calcium and vitamin D, 
bisphosphonates and statins may be considered. Active encouragement of lifestyle 
modifications, e.g. smoking cessation, weight control and exercise, is also important, 
especially in patients with LN [334]. In patients with skin manifestations, photo-protection 
may be beneficial [330].  
 
  
 
46 
covering a wider spectrum of SLE manifestations are needed to fully explore the applicability 
of belimumab. Importantly, real-life experiences are eagerly anticipated. 
 
1.8.3 Adjunctive therapies 
 
Low-dose aspirin may be used for primary prevention of thrombosis in SLE patients with 
APS, whereas long-term use of heparin, low-molecular-weight heparin, or warfarin should be 
used for secondary prevention [330, 405]. In patients with LN, the role of global care in 
addition to immunosuppressive treatment is important. The blood pressure should be 
monitored regularly, and angiotensin converting enzyme (ACE) inhibitors and/or angiotensin 
II receptor blockers (ARBs) should be considered in all LN patients.  
Moreover, the follow-up of SLE patients should include risk factors and routine tests for 
cardiovascular comorbidities, e.g. dyslipidaemia or hyperlipidaemia. The patients should 
regularly be monitored for signs of subclinical infections, especially patients with frequent 
events of neutropenia, as well as for osteopenia and osteoporosis, especially patients 
administered long-term and/or high-dose corticosteroid therapy and post-menopausal women. 
Depending on the medication and the clinical situation, calcium and vitamin D, 
bisphosphonates and statins may be considered. Active encouragement of lifestyle 
modifications, e.g. smoking cessation, weight control and exercise, is also important, 
especially in patients with LN [334]. In patients with skin manifestations, photo-protection 
may be beneficial [330].  
 
  
 47 
2 AIMS 
 
2.1 GENERAL AIMS 
 
The primary aims of this thesis were 
i. to review the current knowledge on pathogenetic mechanisms underlying lupus 
nephritis and B cell aberrations in patients with SLE,  
ii. to identify potential biomarkers of activity, damage, prognosis, and response to 
treatment in patients with active LN following induction immunosuppressive 
treatment and in patients with SLE following BAFF inhibition, as well as  
iii. to investigate the effects of BAFF inhibition on disease activity, chronic damage, 
serologic markers and B cell composition in longitudinally followed patients with 
SLE.  
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2.2 SPECIFIC AIMS 
 
2.2.1 Paper I 
 
In this study, we sought to widen the current knowledge of the role of aPL in patients with 
LN, in particular in patients with LN without concomitant APLN. Renal biopsies from LN 
patients may exhibit vascular changes consistent with APLN to various extents [246, 248-
250], and these changes have been associated with the development of ESRD [248]. 
However, previous studies of LN have demonstrated conflicting results on the impact of aPL 
on renal outcomes [406-413]. 
First, we aimed to investigate potential associations between aPL and LN through analysing 
the occurrence of aPL in patients with LN compared to SLE patients without renal 
involvement. Furthermore, we prospectively followed patients with active biopsy-proven LN 
without histological findings of concomitant APLN and studied aPL positivity and levels 
prior to and after completion of induction treatment, in order to determine the impact of 
immunosuppression on aPL, as well as the impact of aPL on the long-term renal prognosis. 
 
2.2.2 Paper II 
 
With the background of previous implications of TNFR2 in SLE [266-268, 270-275] and LN 
[266, 294, 295], we evaluated serum levels of sTNFR2 in the same prospective LN cohort as 
in Paper I in order to determine the performance of sTNFR2 as a marker of renal activity and 
damage in LN. Furthermore, we sought to evaluate sTNFR2 as a predictor of response to 
treatment and long-term renal prognosis. 
 
2.2.3 Paper III 
 
Given the important role of BLyS and APRIL in B cell homeostasis but their uncertain role in 
LN, we sought to investigate whether and how serum levels of BLyS and APRIL are affected 
by immunosuppressive treatment in patients with active LN. Through correlations with 
clinical data and autoantibodies of known importance in renal SLE, as well as analyses in 
different treatment groups, we further aimed to evaluate serum levels of BLyS and APRIL as 
potential biomarkers of renal activity and chronic damage in LN, as well as their potential 
role as predictors of response to induction treatment. 
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2.2.4 Paper IV 
 
We conducted a prospective study with the aim of investigating the effects of belimumab on 
clinical and serologic outcomes. Post-hoc analyses from the RCTs [201, 202] have facilitated 
the derivation of predictors of response [340]. In our study, we sought to identify baseline 
predictors of treatment response in our real-life setting in order to further contribute to the 
identification of patients who are expected to benefit from this biologic agent. 
 
2.2.5 Paper V 
 
Treatment with belimumab in patients with SLE has been demonstrated to reduce CD20+ B 
cells [399, 414], but no thorough investigation of its immunologic effects has been conducted 
to date. In Paper V, we sought to identify B cell and T cell subset alterations in a prospective 
cohort of SLE patients treated with belimumab, and analyse these changes in relation to 
clinical responses. For this purpose, we made use of mass cytometry, a multi-parametric 
single-cell approach that facilitates the redefinition of cell subsets through unbiased clustering 
and dimensionality reduction. 
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3 MATERIAL AND METHODS 
 
3.1 PATIENTS AND CONTROLS 
 
Since 1995, approximately 525 patients with SLE from the Karolinska University Hospital 
have been included in a large prospective cohort (Karolinska SLE cohort) and are followed 
longitudinally. At the time of enrolment,  
i. clinical SLE disease activity and damage have been assessed,  
ii. serum, plasma, DNA, saliva and urine samples have been collected and 
cryopreserved, and  
iii. levels of autoantibodies, complement activation markers and other routine markers of 
disease activity have been determined.  
Additionally, 320 population-based individuals without SLE have been enrolled, assessed 
clinically using the same indices as for the SLE patients, and are used as controls in clinical 
and translational studies. Samples from these individuals have been collected and 
cryopreserved at the time of enrolment in the same way as from the SLE patients. In the 
Karolinska SLE cohort, approximately 42% of the patients had a history of LN, current or 
previous, at the time of enrolment.  
In addition, patients who have developed an active LN since 1995 have been enrolled in a 
prospective LN programme, which includes the performance of a baseline renal biopsy at 
active disease and a follow-up biopsy after completion of induction therapy. Clinical data and 
blood samples have been collected on both biopsy occasions, and renal tissue has been stored 
for research purposes. The cohorts from which patients and controls were recruited for the 
purpose of the studies included in this thesis are illustrated in Figure 3.1.  
Paper I, Paper II and Paper III comprised 64 patients from the prospective LN cohort. In 
Paper I, patients from the Karolinska SLE cohort were additionally included in a cross-
sectional analysis and were classified as patients with (n=204) or without (n=294) current or 
previous LN. Population-based individuals without SLE (n=314) were enrolled as controls in 
Paper II. Finally, 64 population-based controls, individually matched for age, sex, and 
origin, were included in Paper III. Characteristics of patients and controls included in these 
papers are presented in Table 3.1, and exhibit expected distributions regarding sex and age, 
and higher global disease activity among patients with active renal disorder. The vast 
majority of the patients were Caucasians. 
Following confirmation of active LN, the patients received induction treatment with 
corticosteroids combined with cyclophosphamide (n=45), mycophenolate mofetil (n=11), 
rituximab (n=7) or azathioprine (n=1). A follow-up was conducted after completion of 
induction treatment, including post-treatment renal biopsies. 
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Fifty-eight patients with a moderately active SLE despite standard of care treatment from the 
Karolinska (n=30), Skåne (n=19) and Linköping (n=9) University Hospitals were treated with 
belimumab between 2011 and 2015 and were enrolled in the prospective cohort of Paper IV. 
The patients were followed longitudinally with visits at baseline and at months 3, 6, 12, 24, 
36 and 48, or more frequently if clinically indicated. A fraction of the patients from the 
Karolinska University Hospital (n=23) were also included in Paper V. Baseline 
characteristics of these patients are presented in Table 3.2 and Table 3.3. As in the 
prospective LN cohort, the patients exhibited the expected distributions regarding sex and 
age, and they were mainly Caucasians. 
All patients fulfilled the 1982 revised ACR criteria [21] and/or the SLICC criteria [23] for 
classification of SLE.  
 
 
Figure 3.1. Cohorts from which patients and controls were recruited  
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Table 3.2. Baseline characteristics: Paper IV 
 Paper IV (n=58) 
Sex  
Female; n (%) 53 (91.4%) 
Ethnicity  
Caucasian; n (%) 55 (94.8%) 
Other; n (%) 3 (5.2%) 
Age (years); M (IQR) 41.3 (31.2–51.0) 
SLE disease duration (years); M (IQR) 7.8 (4.3–14.2) 
SLEDAI-2K; M (IQR) 8.0 (4.0–14.0) 
SLAM-R; M (IQR) 13.5 (9.8–17.5); n=30 
PGA (100 mm VAS); M (IQR) 50.0 (50.0–70.5); n=57 
SDI; M (IQR) 1.0 (0.0–2.0) 
Reason for belimumab   
Arthritis; n (%) 27 (48.2%) 
Mucocutaneous manifestations; n (%) 27 (48.2%) 
Haematologic manifestations; n (%) 10 (17.5%) 
Lupus nephritis; n (%) 7 (12.3%) 
Neuropsychiatric lupus; n (%) 4 (7.0%) 
Serositis; n (%) 3 (5.3%) 
General manifestations; n (%) 2 (3.5%) 
Serologic activity; n (%) 1 (1.8%) 
Respiratory; n (%) 1 (1.8%) 
Smoking status  
Current smokers; n (%) 7 (12.3%); n=57 
Former smokers; n (%) 20 (35.1%); n=57 
Never smokers; n (%) 30 (52.6%); n=57 
M: median; IQR: interquartile range. 
 
Table 3.3. Baseline characteristics: Paper V 
 Paper V (n=23) 
Sex  
Female; n (%) 19 (82.6%) 
Ethnicity  
Caucasian; n (%)  22 (95.7%) 
African; n (%)  1 (4.3%) 
Age (years); M (IQR) 38.4 (30.4–50.3) 
SLE disease duration (years); M (IQR) 7.7 (4.3–14.4) 
SLEDAI-2K; M (IQR) 9 (7–15) 
M: median; IQR: interquartile range. 
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3.2 SLE DISEASE ACTIVITY 
 
Global SLE disease activity was assessed using the SLEDAI-2K [185], the SLAM-R [188, 
189], the BILAG index [194, 415], the PGA on 100 mm VAS [186], and the SELENA-
SLEDAI PGA (scored 0–3) [195]. We also made use of the modified SLEDAI-2K 
(mSLEDAI-2K) [187].  
 
3.3 ORGAN DAMAGE 
 
Organ damage was evaluated using the SDI [196].  
 
3.4 QUALITY OF LIFE 
 
In Paper IV, Quality of life (QoL) was evaluated using patient reports for pain, fatigue and 
general health on 100 mm VAS. Global health was determined by the EuroQoL Research 
Foundation [197] 5 Dimension (EQ-5D) health questionnaire, scored according to the UK 
tariff [198]. Functional status was assessed using the Stanford HAQ functional disability 
index [199]. 
 
3.5 RENAL FUNCTION 
 
The urinary status was evaluated using urine test strips and urinary sediment. The proteinuria 
was estimated by the 24-hour urine albumin excretion (g/day). Renal function was assessed 
by the plasma creatinine concentration (µmol/L) and by the eGFR, as determined by the 
Modification of Diet in Renal Disease (MDRD) Study equation [416, 417]. 
In Paper I and Paper II, the long-term renal outcome was assessed using the last eGFR and 
the last CKD stage, as defined by the updated guidelines of the Kidney Disease Outcomes 
Quality Initiative by the National Kidney Foundation [418-420]. 
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3.6 RENAL HISTOLOGY 
 
The renal biopsies were performed under the guidance of ultrasonography. The renal tissue 
was evaluated using light microscopy, immunofluorescence and electron microscopy. The 
same pathologist, Birgitta Sundelin, assessed all renal biopsies in Paper I, Paper II and 
Paper III, according to the 2003 ISN/RPS classification of LN [176]. The biopsies were also 
scored for activity and chronicity features, using the Activity Index and the Chronicity Index, 
respectively [181]. 
 
3.7 SEROLOGIC ACTIVITY 
 
In Paper I, Paper II and Paper III, anti-dsDNA antibody levels (positive values ≥10 
IU/mL) were measured using multiplex immunoassays (BioPlex 2200 System, Bio-Rad 
Laboratories, Inc., Hercules, California, USA). In Paper IV and Paper V, titres of anti-
dsDNA antibodies were determined using the Crithidia luciliae substrate based 
immunofluorescence technique (CLIFT) [421] at every visit, and serum anti-dsDNA antibody 
levels were determined by addressable laser bead immunoassay (ALBIA) at the end of the 
study period, using the FIDIS Connective profile MX 117 kit (Theradiag, Paris, France).  
Levels of antibodies to complement protein C1q (anti-C1q; reference values <14 U/mL) were 
determined using ELISA (Alegria, ORGENTEC Diagnostika GmbH, Germany). 
Complement protein C3 and complement protein C4 levels were determined using 
nephelometry. 
In Paper I, serum levels of IgG and IgM anticardiolipin antibodies (aCL) and anti-β2-
glycoprotein I antibodies (anti-β2-GPI) (positive values ≥20 U/mL) were determined using 
multiplex immunoassays (BioPlex 2200 System, Bio-Rad Laboratories, Inc., Hercules, 
California, USA). Presence or absence of lupus anticoagulant (LA) was determined by the 
dilute Russell's viper venom time, followed by a confirmatory test. Total Ig levels were 
measured by nephelometry. 
In Paper II, serum levels of sTNFR2 were determined using ELISA kits from R&D Systems 
(Minneapolis, Minnesota, USA). In Paper III and Paper IV, Quantikine ELISA (R&D 
Systems, Bio-Techne, Minneapolis, Minnesota, USA) was used for the detection of serum 
BLyS. Concentrations of circulating APRIL were determined using Platinum ELISA 
(Affymetrix, eBioscience, Vienna, Austria).  
All assays were undertaken according to the manufacturer's instructions and generated an 
approximate mean coefficient of variation of 6%. 
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3.8 CELL ANALYSES 
 
In Paper V, the PBMC samples were analysed by a CyTOF2 (Fluidigm Inc., South San 
Francisco, CA, USA) mass cytometer (cytometry by time-of-flight, CyTOF). Two million 
thawed PBMCs from each sample were stained directly ex vivo using a panel of 30 different 
metal-tagged probes to surface antigens. Cell counts were corrected by the absolute 
lymphocyte count at the respective visit.   
Bead-based normalisation of the CyTOF data was applied for correction of signal fluctuations 
[422]. The cells were gated by event length, DNA (0.125 µM Iridium 191/193 or MaxPar® 
Intercalator-Iridium, Fluidigm), beads and viability (Cisplatin, Fluidigm). B cells were gated 
as CD20+CD3e-, plasma cells as CD19+CD38+CD27+CD20-, T cells as CD3e+CD20-, and 
monocytes as CD14+CD20-CD3e-. 
Flow cytometry was performed for confirmatory purposes. Cryopreserved PBMC samples 
were thawed, and the cell suspensions were stained for 30 minutes at 4°C in PBS containing 
0.5% human serum with mouse anti-human monoclonal antibodies. Dead cells were excluded 
using the 7-Amino Actinomycin D (BioLegend Inc., San Diego, CA, USA). Flow cytometric 
analysis was carried out using an LSRFortessa cell analyser (BD Biosciences, San Jose, CA, 
USA), and the data were processed using FlowJo software (FlowJo LLC, Ashland, OR, 
USA). To distinguish cells expressing an antigen from cells lacking expression of the 
respective antigen, the cut-off was determined by fluorescent minus one (FMO) controls 
[423]. 
 
3.9 DEFINITIONS OF TREATMENT RESPONSE 
 
3.9.1 Clinical global response 
 
In Paper IV and Paper V, response to treatment was defined in line with the SLE responder 
index (SRI) [203] as  
i. a reduction of ≥4 points in SLEDAI-2K,  
ii. no new BILAG A and no more than 1 new BILAG B, and  
iii. no deterioration in PGA-VAS by ≥30 mm.  
Low disease activity was defined according to the Lupus Low Disease Activity State 
(LLDAS) [424] as  
i. a SLEDAI-2K ≤4,  
ii. no activity in major organ systems,  
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iii. no haemolytic anaemia or gastrointestinal activity,  
iv. no new SLE activity,  
v. a SELENA-SLEDAI PGA ≤1,  
vi. a prednisone equivalent dose of ≤7.5 mg/day, and  
vii. well tolerated doses of immunosuppressive drugs and/or approved biologic agents. 
In Paper IV, attainment of mSLEDAI-2K=0 was also analysed as an additional treatment 
response outcome, reflecting clinical remission according to the SLEDAI-2K when the 
serologic items are excluded. 
 
3.9.2 Clinical renal response 
 
In line with the ACR response criteria for proliferative and membranous renal disease in SLE 
clinical trials [208], clinical responders (CRs) in Paper I, Paper II and Paper III were 
required to fulfil three conditions:  
i. at least 50% reduction in proteinuria resulting in levels ≤2 g/day, 
ii. normal eGFR, defined as >90 mL/min/1.73 m2, or, if abnormal at baseline, improved 
eGFR by ≥25%, and 
iii. inactive urinary sediment, defined as ≤5 red blood cells/high power field, ≤5 white 
blood cells/high power field and no cellular casts.  
In Paper III, patients fulfilling these three criteria were additionally divided into clinical 
complete responders (CCRs) and clinical partial responders (CPRs), based on their follow-up 
proteinuria level. Complete responders were required to have a level of proteinuria below 0.2 
g/day, whereas partial response required proteinuria levels between 0.2 g/day and 2 g/day. 
 
3.9.3 Histological renal response 
 
In Paper II, and Paper III, we made use of the Activity Index [181] and the 2003 ISN/RPS 
classification of LN [176] to define the histological renal outcome following induction 
treatment for active LN. In Paper III, we subdivided the histological response into partial 
and complete response. In Paper II, only the definition of partial response was utilised and 
the patients were stratified into histological responders and histological non-responders.  
According to our definition, complete histological response required 
i. an improvement of ≥50% in the Activity Index score compared to baseline, and 
ii. absence of active lesions in the follow-up renal biopsy: ISN/RPS class I, II, III (C), or 
IV-S/G (C). 
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Partial histological response still required an improvement of ≥50% in the Activity Index 
score compared to baseline, but allowed residual active lesions or a residual membranous 
pattern in the post-treatment renal biopsy: ISN/RPS class III (A), III (A/C), IV-S/G (A), IV-
S/G (A/C), or V [171, 229]. 
 
3.10 STATISTICS 
 
Descriptive statistics were used for characterisation of the study populations. Such data are 
presented as medians or means and ranges or interquartile ranges, or as counts and 
percentages.  
For comparisons between related samples, the paired samples t-test was used for normally 
distributed variables, and the non-parametric Wilcoxon signed-rank test was used for non-
normally distributed samples. Comparisons between independent samples were made using 
the Student's t-test for normally distributed data, and the Mann-Whitney U test for variables 
with non-normal distributions. Comparisons of proportions between groups were performed 
using the Pearson Chi-square or the Fisher's exact test. Correlations were performed using the 
Pearson product-moment correlation coefficient for normally distributed data and the 
Spearman’s rank correlation coefficient for non-normally distributed samples. Data from the 
assessment of autoantibody levels were bounded by the detection limits of the assays. Values 
under the lower detection limit were set to half the lower limit value, and values over the 
upper detection limit were set to twice the upper limit value.  
To investigate the performance of specific items as predictors of treatment response, receiver 
operating characteristic (ROC) analysis was used with baseline values as classifiers, and 
ROC-curves were constructed in order to evaluate the candidate predictor and determine the 
optimal threshold value. 
In the cross-sectional part of Paper I, associations between current or previous LN and the 
presence of IgG or IgM aPL, LA, anti-dsDNA and concomitant APS were assessed using 
logistic regression and are presented as odds ratios (ORs) and their respective 95% 
confidence interval (CI).  
To investigate the role of aPL and sTNFR2 in long-term renal outcomes, as well as in renal 
activity, renal damage, and global disease activity, in the prospective LN cohort of Paper I 
and Paper II, linear mixed models for repeated measures were used. Separate models were 
built for each outcome of interest. These outcomes were separately included as the dependent 
variable in the linear mixed models, with LN patient visits as repeated and fixed effects, aPL 
or sTNFR2 levels as a covariate, and patients as a random effect. For the long-term renal 
outcome, the models were adjusted for the total observation time in years. 
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Linear mixed models for repeated measurements were also used in Paper IV to facilitate the 
investigation of treatment outcomes, each of which was included in the respective model as 
the dependent variable. Patient visits were included as repeated and fixed effects, and patients 
as a random effect. The models were adjusted for age, sex, ethnicity, and clinical practice 
setting. In addition, Cox regression models were used in Paper IV for the identification of 
baseline predictors of treatment response. 
For phenotypic B cell subset separation and dimensionality reduction into a two-dimensional 
space in Paper V, we performed Barnes-Hut t-distributed stochastic neighbour embedding (t-
SNE) using the Automatic Classification of Cellular Expression by Nonlinear Stochastic 
Embedding (ACCENSE) software, with a perplexity value of 30 [425]. The PhenoGraph 
algorithm was used for clustering [426]. 
P-values <0.05 were considered statistically significant. In several cases of multiple 
comparisons, Bonferroni or Benjamini-Hochberg correction was applied. In Paper V, the P-
values corresponding to comparisons of baseline cell counts between patient subgroups with 
regard to treatment response, derived from application of the Mann-Whitney U test, were 
sanity checked using randomisation of patient-to-value assignment. 
The statistical analyses were performed using the IBM SPSS Statistics 21, 22 and 23 
softwares (IBM Corp., Armonk, New York, USA), the R package lme4, and in Paper V we 
used the python package SciPy for correlation analyses and the paired.r function from the R 
psych package for comparisons of correlations.  
 
3.11 ETHICS 
 
Written informed consent in accordance with the ethical principles of the declaration of 
Helsinki was obtained prior to enrolment from all adult individuals participating in the studies 
of this thesis, and also from the next of kin, caretakers, or guardians on behalf of the minors 
or children enrolled. The study protocols were reviewed and approved by the regional ethics 
review board at Karolinska Institutet, and for Paper IV also by the regional ethics review 
boards at Lund University and at Linköping University.  
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4 RESULTS 
 
4.1 PROSPECTIVE LN COHORT 
 
In the prospective LN cohort of Paper I, Paper II and Paper III, 52 cases were classified as 
proliferative LN with or without a concurrent membranous pattern (ISN/RPS class III/IV±V), 
and 12 cases were classified as membranous LN (ISN/RPS class V), based on the baseline 
renal biopsies. None of these patients had a concomitant diagnosis of APLN, and no patient 
was diagnosed with renal artery or renal vein thrombosis, either concurrently with or prior to 
LN. Out of 63 patients in whom data were available, seven (11.1%) had a diagnosis of and 
treatment for diabetes, and 34 (54%) had a diagnosis of and treatment for hypertension. 
Results from the evaluation of the renal biopsies, SLEDAI-2K scores, proteinuria, creatinine 
concentrations and eGFR are presented in Table 4.1. Proportions of patients with aPL and 
serum aPL levels in the different subgroups are presented in Table 4.2. 
 
4.1.1 Renal clinical response 
 
Following treatment, 48 patients were considered clinical responders, 26 attaining complete 
and 22 attaining partial clinical response, and 16 patients were considered clinical non-
responders.  
In the proliferative LN subgroup, 41 patients were regarded as clinical responders, 25 
complete and 16 partial, and 11 as clinical non-responders. In the membranous LN subgroup, 
seven patients were clinical responders, and five patients were clinical non-responders. No 
stratification into complete and partial response was done in this patient subgroup because of 
the low number of patients.   
 
4.1.2 Renal histological response 
 
In the combined patient group, 49 LN patients were considered histological responders, 25 
complete and 24 partial, and 14 patients were considered histological non-responders.  
Among patients with proliferative LN, 43 had responded histologically following treatment, 
23 patients attaining complete response and 20 patients showing partial responses, whereas 
nine patients did not achieve histological response. In the membranous LN subgroup, six 
 
61 
4 RESULTS 
 
4.1 PROSPECTIVE LN COHORT 
 
In the prospective LN cohort of Paper I, Paper II and Paper III, 52 cases were classified as 
proliferative LN with or without a concurrent membranous pattern (ISN/RPS class III/IV±V), 
and 12 cases were classified as membranous LN (ISN/RPS class V), based on the baseline 
renal biopsies. None of these patients had a concomitant diagnosis of APLN, and no patient 
was diagnosed with renal artery or renal vein thrombosis, either concurrently with or prior to 
LN. Out of 63 patients in whom data were available, seven (11.1%) had a diagnosis of and 
treatment for diabetes, and 34 (54%) had a diagnosis of and treatment for hypertension. 
Results from the evaluation of the renal biopsies, SLEDAI-2K scores, proteinuria, creatinine 
concentrations and eGFR are presented in Table 4.1. Proportions of patients with aPL and 
serum aPL levels in the different subgroups are presented in Table 4.2. 
 
4.1.1 Renal clinical response 
 
Following treatment, 48 patients were considered clinical responders, 26 attaining complete 
and 22 attaining partial clinical response, and 16 patients were considered clinical non-
responders.  
In the proliferative LN subgroup, 41 patients were regarded as clinical responders, 25 
complete and 16 partial, and 11 as clinical non-responders. In the membranous LN subgroup, 
seven patients were clinical responders, and five patients were clinical non-responders. No 
stratification into complete and partial response was done in this patient subgroup because of 
the low number of patients.   
 
4.1.2 Renal histological response 
 
In the combined patient group, 49 LN patients were considered histological responders, 25 
complete and 24 partial, and 14 patients were considered histological non-responders.  
Among patients with proliferative LN, 43 had responded histologically following treatment, 
23 patients attaining complete response and 20 patients showing partial responses, whereas 
nine patients did not achieve histological response. In the membranous LN subgroup, six 
 62 
patients were classified as histological responders, five showed no histological improvement, 
and one patient did not undergo post-treatment renal biopsy. 
 
4.1.3 Serologic activity following treatment 
 
At baseline, 59 patients (94%) were positive for anti-dsDNA and 46 (73%) for anti-C1q 
antibodies. Post-treatment, 48 LN patients (79%) remained positive for anti-dsDNA and 30 
(47%) for anti-C1q antibodies.  
Serum levels of both anti-dsDNA and anti-C1q antibodies displayed significant decreases 
following treatment (P<0.001 for both), irrespective of the clinical or the histological 
treatment outcome.   
 
4.1.4 Associations between aPL and LN 
 
In the cross-sectional analysis of 498 SLE patients (Paper I), we found no association 
between positivity for aPL at the time of enrolment and current or previous LN. Moreover, 
we found no association between LA positivity at any time prior to enrolment and LN. 
Further, both aPL positivity and serum levels of aPL were similar in patients with active LN 
and patients with non-renal SLE (Table 4.2). In contrast, we found that definite diagnosis of 
APS [230] was associated with current or previous LN (OR: 1.98 (95% CI: 1.19–3.28); 
P=0.009), and, as expected, anti-dsDNA positivity was also associated with current or 
previous LN (OR: 2.38 (95% CI 1.64–3.64); P<0.001). 
 
4.1.5 Associations between aPL and short-term renal outcomes in LN 
 
In the prospective LN cohort, creatinine levels at baseline were higher in LN patients with 
versus without IgG aCL (P=0.03) and anti-β2-GPI (P=0.02), but similar in patients with and 
without IgM aCL or anti-β2-GPI. Similar findings were observed post-treatment (Figure 4.1).  
In contrast, no correlation was found between serum aPL levels and Activity or Chronicity 
Index scores in renal biopsies, SLEDAI-2K, 24-h U-albumin, anti-dsDNA levels, or age, 
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patients were classified as histological responders, five showed no histological improvement, 
and one patient did not undergo post-treatment renal biopsy. 
 
4.1.3 Serologic activity following treatment 
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(47%) for anti-C1q antibodies.  
Serum levels of both anti-dsDNA and anti-C1q antibodies displayed significant decreases 
following treatment (P<0.001 for both), irrespective of the clinical or the histological 
treatment outcome.   
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APS [230] was associated with current or previous LN (OR: 1.98 (95% CI: 1.19–3.28); 
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previous LN (OR: 2.38 (95% CI 1.64–3.64); P<0.001). 
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without IgM aCL or anti-β2-GPI. Similar findings were observed post-treatment (Figure 4.1).  
In contrast, no correlation was found between serum aPL levels and Activity or Chronicity 
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(P=0.03) and IgM anti-β2-GPI (P=0.046), whereas proportions of patients with IgG aPL 
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remained unchanged (Table 4.2). Both IgG and IgM aPL levels decreased following 
treatment (P<0.001 for all; Table 4.2). In order to investigate whether the reductions in aPL 
levels were dependent on the induction treatment regimen, we stratified the patients of the 
prospective LN cohort into patients treated with cyclophosphamide or rituximab (CYC/RTX; 
n=52) and patients treated with mycophenolate mofetil (MMF; n=11). Levels of IgG/IgM 
aCL and anti-β2-GPI showed decreases in both treatment groups (Table 4.3). 
In order to clarify whether these reductions were due to decreases in the total Ig levels 
following treatment, we compared the ratios of aPL levels to total Ig levels before and after 
treatment. Although total IgG and IgM levels decreased following treatment (P=0.02 and 
P=0.01, respectively), the ratios of IgG aPL to total IgG also decreased for both aCL (P=0.01) 
and anti-β2-GPI (P=0.02). In contrast, ratios of IgM aCL to total IgM (P=0.67) and IgM anti-
β2-GPI to total IgM were stable (P=0.55).  
Baseline aPL levels did not differ between clinical responders and patients who did not show 
clinical improvements (P=NS for all). We observed reductions in serum levels of both IgG 
and IgM aPL in clinical responders, but not in non-responding patients (Table 4.5). In 
contrast, anti-dsDNA levels decreased in both responding (P<0.001) and non-responding 
(P=0.02) LN patients.   
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Table 4.3. Comparisons with regard to the induction treatment regimen 
Prospective LN cohort Active LN Treated LN P-value 
IgG aCL CYC/RTX; n=52 2.0 (0.8–8.2) 0.8 (0.8–2.0) <0.001 ↓ MMF; n=11 1.9 (0.8–4.8) 0.8 (0.8–0.8) 0.03 ↓ 
     
IgM aCL CYC/RTX; n=52 0.9 (0.3–4.0) 0.8 (0.3–2.8) 0.001 ↓ MMF; n=11 0.6 (0.2–1.9) 0.4 (0.1–1.2) 0.007 ↓ 
     
     
IgG anti-β2-GPI 
CYC/RTX; n=52 2.0 (0.7–14.0) 0.7 (0.7–3.7) <0.001 ↓ 
MMF; n=11 2.4 (0.7–5.2) 0.7 (0.7–1.4) 0.03 ↓ 
     
IgM anti-β2-GPI 
CYC/RTX; n=52 1.1 (0.4–5.0) 1.0 (0.3–3.3) 0.002 ↓ 
MMF; n=11 0.9 (0.3–2.4) 0.6 (0.2–1.3) 0.007 ↓ 
Data are presented as medians (interquartile ranges). Levels of aCL are in IU/mL. Levels of 
anti-β2-GPI are in U/mL. Downward arrows (↓) signify significant decreases.  
CYC: cyclophosphamide; RTX: rituximab; MMF: mycophenolate mofetil. 
 
 
Table 4.5. Comparisons with regard to clinical response to induction treatment 
Prospective LN cohort Active LN Treated LN P-value 
IgG aCL Responders 2.6 (0.8–8.2) 0.8 (0.8–2.0) <0.001 ↓ Non-responders 0.8 (0.8–1.9) 0.8 (0.8–0.8) 0.07 
     
IgM aCL Responders 0.8 (0.2–3.9) 0.6 (0.1–2.6) 0.002 ↓ Non-responders 0.9 (0.4–2.9) 1.0 (0.2–2.1) 0.03 
     
IgG anti-β2-GPI 
Responders 2.6 (0.7–13.0) 0.7 (0.7–3.2) <0.001 ↓ 
Non-responders 0.7 (0.7–3.0) 0.7 (0.7–1.5) 0.03 
     
IgM anti-β2-GPI 
Responders 1.0 (0.3–4.6) 0.7 (0.2–3.2) 0.003 ↓ 
Non-responders 0.9 (0.5–4.5) 1.3 (0.3–3.1) 0.03 
Data are presented as medians (IQR). Levels of aCL are in IU/mL. Levels of anti-β2-GPI are 
in U/mL. P-values in bold remained statistically significant after Bonferroni correction. 
Downward arrows (↓) signify significant decreases after Bonferroni correction. 
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Figure 4.1. Creatinine levels (µmol/L) in LN patients with and without IgG aPL 
Circles and stars denote outliers. 
 
4.1.6 Serum sTNFR2 as a biomarker of treatment response 
 
Serum sTNFR2 levels were elevated in LN patients compared to non-SLE controls, both at 
baseline (P<0.001) and post-treatment (P<0.001). Baseline sTNFR2 levels did not differ 
between patients with proliferative and membranous LN (P=0.49). Following induction 
treatment, significant reductions in sTNFR2 levels were observed within the entire patient 
cohort (P<0.001) and in the proliferative LN subgroup (P<0.001), but not in patients with 
membranous LN (P=0.18).  
Serum levels of sTNFR2 decreased following treatment in both responders (clinical and 
histological) and non-responders (clinical and histological) in the combined patient cohort 
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and in the proliferative LN subgroup. In the membranous LN subgroup, sTNFR2 levels 
decreased in clinical responders (P=0.028), but not in clinical non-responders. 
Baseline serum sTNFR2 levels did not differ between clinical responders and clinical non-
responders or between histological responders and histological non-responders, either in the 
entire LN cohort or the proliferative LN subgroup. In contrast, within the membranous LN 
subgroup baseline sTNFR2 levels were higher in clinical responders versus clinical non-
responders (P=0.048), as well as in histological responders versus histological non-
responders (P=0.03). According to ROC-curve analysis, baseline sTNFR2 levels 
distinguished clinical responders from clinical non-responders in the membranous LN 
subgroup, with a level of 8.6 ng/mL yielding a sensitivity of 85.7% and a specificity of 
80.0%. Similarly, baseline sTNFR2 levels distinguished histological responders from 
histological non-responders within the membranous LN subgroup, with a level of 9.0 ng/mL 
yielding a sensitivity of 83.3% and a specificity of 80.0% (Figure 4.2). 
 
 
Figure 4.2. Serum sTNFR2 as a predictor of treatment response in membranous LN 
The ROC-curves illustrate baseline serum sTNFR2 levels as predictors of clinical (A) and 
histological (B) response to treatment in patients with membranous LN (MLN).  
AUC: area under the curve; CI: confidence interval.  
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4.1.7 Serum sTNFR2 as a biomarker of renal damage 
 
Baseline serum sTNFR2 levels correlated with Chronicity Index scores in both baseline 
(r=0.34, P=0.006) and post-treatment (r=0.43, P<0.001) renal biopsies, and post-treatment 
sTNFR2 levels correlated with post-treatment Chronicity Index scores (r=0.55, P<0.001). We 
also found that post-treatment, but not baseline, sTNFR2 levels correlated with post-treatment 
Activity Index scores (r=0.28, P=0.03) and post-treatment proteinuria (r=0.42, P=0.001). No 
correlations were observed between baseline or post-treatment sTNFR2 and SLEDAI-2K, 
eGFR, C3 or C4 levels, prednisone equivalent dosages, anti-dsDNA, anti-C1q, or age. 
Further, linear mixed model analysis showed that baseline serum sTNFR2 levels were 
associated with increasing Chronicity Index scores following treatment (P=0.003). 
 
4.1.8 Evaluation of BLyS and APRIL in LN 
 
In the prospective LN cohort, the median serum BLyS level was 1.5 ng/mL at baseline and 
1.7 ng/mL post-treatment. In 64 individually matched controls, the median level was 1.1 
ng/mL. Both at baseline and post-treatment, BLyS levels were higher in patients than in 
controls (P<0.001 for both). 
The median serum APRIL level was 7.1 ng/mL at baseline and 5.4 ng/mL post-treatment for 
the patients, and 3.6 ng/mL for the controls. Serum levels of APRIL were significantly higher 
in patients compared to controls at baseline (P=0.005), but not post-treatment (P=0.14). 
Consistently, significant reductions in APRIL levels were observed following induction 
therapy (P<0.001). 
Following treatment, serum levels of BLyS remained unchanged regardless of either clinical 
or histological outcome, whereas serum levels of APRIL decreased in both clinical 
responders (P=0.002) and clinical non-responders (P=0.017), as well as in complete 
histological responders (P=0.010) and histological non-responders (P=0.016), but no 
significant change was seen in patients showing a partial histological response (P=0.072). 
We performed ROC-curve analysis for the evaluation of baseline BLyS levels as a predictor 
of response to treatment, and the area under the curve (AUC) was found to be 0.71. Further 
analysis showed that low baseline BLyS levels had a high positive predictive value (PPV) for 
both clinical and histological response. The optimal threshold baseline BLyS value was found 
to be 1.5 ng/mL, being similar to the median baseline serum concentration of BLyS in LN 
patients. In the entire LN group, baseline BLyS levels below this threshold value displayed an 
87% PPV for clinical response and an 83% PPV for histological response. In the proliferative 
LN subgroup, the corresponding PPV was 92% for clinical response and 84% for histological 
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response. In contrast, ROC-curve analysis for baseline APRIL levels as a predictor of 
treatment response revealed no predictive power for serum APRIL. 
Comparing baseline and post-treatment BLyS levels in the different treatment groups, we 
observed numerical increases in BLyS levels in cyclophosphamide-treated and rituximab-
treated patients, and a numerical decrease in patients treated with mycophenolate mofetil. 
Combining the cyclophosphamide and rituximab subgroups, a significant difference was seen 
compared to the mycophenolate mofetil subgroup post-treatment (P=0.02) while no 
difference was found at baseline (P=0.90). 
APRIL levels decreased in cyclophosphamide-treated LN patients (P=0.006). This decrease 
did not reach significance in the mycophenolate mofetil (P=0.065) and the rituximab 
(P=0.063) treatment groups. 
No correlation was found between BLyS or APRIL and either anti-dsDNA or anti-C1q 
autoantibodies.  
 
4.1.9 Long-term renal outcomes 
 
In the prospective LN cohort, the long-term follow-up median eGFR was 80 mL/min/1.73 m2 
(range: 17–149), and the patients were stratified into CKD stage 1 (n=22), stage 2 (n=26), 
stage 3 (n=12), and stage 4 (n=3). No patient had developed ESRD (CKD stage 5). Long-
term follow-up eGFR did not differ from eGFR either at active LN (P=0.79) or after 
completion of induction treatment (P=0.21). 
Neither baseline nor post-treatment aPL levels correlated with the long-term follow-up eGFR, 
and no association was found with long-term changes in eGFR in linear mixed model 
analysis. Long-term eGFR did not differ between aPL-positive and aPL-negative LN patients 
either at baseline or post-treatment. Consistently, neither aPL positivity nor serum levels of 
aPL at baseline or post-treatment differed between LN patients with a long-term follow-up 
CKD stage 1–2 and patients with a CKD stage of ≥3. 
Baseline sTNFR2 levels were associated with decreases in eGFR from baseline through the 
last follow-up (P=0.02). This association remained significant after adjustment for the follow-
up duration estimated in years (P=0.046). Similarly, post-treatment sTNFR2 levels were 
associated with decreases in eGFR from post-treatment through the last follow-up, before 
(P=0.03) and after (P=0.01) adjustment for the follow-up duration. 
Baseline sTNFR2 levels did not differ between LN patients with a CKD stage 1–2 and 
patients with a CKD stage ≥3 at the last follow-up (P=0.13). In contrast, post-treatment 
sTNFR2 levels were higher in LN patients with a long-term follow-up CKD stage ≥3 
(median: 8.6 ng/mL; range: 2.28–11.96) compared with patients with a CKD stage 1–2 
 
70 
response. In contrast, ROC-curve analysis for baseline APRIL levels as a predictor of 
treatment response revealed no predictive power for serum APRIL. 
Comparing baseline and post-treatment BLyS levels in the different treatment groups, we 
observed numerical increases in BLyS levels in cyclophosphamide-treated and rituximab-
treated patients, and a numerical decrease in patients treated with mycophenolate mofetil. 
Combining the cyclophosphamide and rituximab subgroups, a significant difference was seen 
compared to the mycophenolate mofetil subgroup post-treatment (P=0.02) while no 
difference was found at baseline (P=0.90). 
APRIL levels decreased in cyclophosphamide-treated LN patients (P=0.006). This decrease 
did not reach significance in the mycophenolate mofetil (P=0.065) and the rituximab 
(P=0.063) treatment groups. 
No correlation was found between BLyS or APRIL and either anti-dsDNA or anti-C1q 
autoantibodies.  
 
4.1.9 Long-term renal outcomes 
 
In the prospective LN cohort, the long-term follow-up median eGFR was 80 mL/min/1.73 m2 
(range: 17–149), and the patients were stratified into CKD stage 1 (n=22), stage 2 (n=26), 
stage 3 (n=12), and stage 4 (n=3). No patient had developed ESRD (CKD stage 5). Long-
term follow-up eGFR did not differ from eGFR either at active LN (P=0.79) or after 
completion of induction treatment (P=0.21). 
Neither baseline nor post-treatment aPL levels correlated with the long-term follow-up eGFR, 
and no association was found with long-term changes in eGFR in linear mixed model 
analysis. Long-term eGFR did not differ between aPL-positive and aPL-negative LN patients 
either at baseline or post-treatment. Consistently, neither aPL positivity nor serum levels of 
aPL at baseline or post-treatment differed between LN patients with a long-term follow-up 
CKD stage 1–2 and patients with a CKD stage of ≥3. 
Baseline sTNFR2 levels were associated with decreases in eGFR from baseline through the 
last follow-up (P=0.02). This association remained significant after adjustment for the follow-
up duration estimated in years (P=0.046). Similarly, post-treatment sTNFR2 levels were 
associated with decreases in eGFR from post-treatment through the last follow-up, before 
(P=0.03) and after (P=0.01) adjustment for the follow-up duration. 
Baseline sTNFR2 levels did not differ between LN patients with a CKD stage 1–2 and 
patients with a CKD stage ≥3 at the last follow-up (P=0.13). In contrast, post-treatment 
sTNFR2 levels were higher in LN patients with a long-term follow-up CKD stage ≥3 
(median: 8.6 ng/mL; range: 2.28–11.96) compared with patients with a CKD stage 1–2 
 71 
(median: 5.2 ng/mL; range: 1.95–18.83; P=0.008). ROC-curve analysis showed that post-
treatment sTNFR2 levels could distinguish patients with a long-term follow-up CKD stage 1–
2 from patients with a CKD stage ≥3, with a level of 7.1 ng/mL yielding a sensitivity of 
73.3% and a specificity of 75.0% (Figure 4.3).  
 
 
 
Figure 4.3. Serum sTNFR2 as a predictor of the long-term renal outcome 
Long-term follow-up eGFR correlated inversely with both baseline (A) and post-treatment 
(B) serum sTNFR2 levels. Post-treatment sTNFR2 levels were higher in LN patients with a 
CKD stage ≥3 at the last follow-up compared with patients with a CKD stage 1–2 (C). Post-
treatment sTNFR2 levels could distinguish between patients with a CKD stage 1–2 and ≥3 at 
the last follow-up (D), with a level of 7.1 ng/mL yielding a sensitivity of 73.3% and a 
specificity of 75.0%.  
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4.2 STUDIES OF BELIMUMAB 
 
4.2.1 Effects on disease activity and organ damage 
 
In Paper IV, SLE disease activity decreased over time according to SLEDAI-2K (P<0.0001), 
SLAM-R (P<0.0001), and PGA VAS (P<0.0001), and no significant damage progression 
according to SDI was observed during follow-up (P=0.08). 
 
4.2.1.1 Patients with renal involvement 
 
In seven patients, renal involvement was among the reasons for initiating belimumab 
treatment (Table 3.2). In this patient subgroup, proteinuria levels decreased over time 
(P=0.045), and the sum of the renal components of the SLEDAI-2K (proteinuria, haematuria, 
pyuria, urinary casts) was also found to decrease (P=0.035). 
 
4.2.2 Immunologic markers 
 
We observed decreasing anti-dsDNA during follow-up, both according to CLIFT (P=0.03; 
n=58) and ALBIA (P=0.0008; n=54). C4 levels increased (P<0.0001; n=58), whereas C3 
levels remained stable (P=0.19; n=58). Seroconversion to non-detectable anti-dsDNA titres 
was noted in 10 patients (35.7%; n=28) after a median time of 6.6 months, and C3 and C4 
levels were normalised in 12 patients (38.7%; n=31) after a median time of 7.0 months.  
Serum BLyS levels were found to increase during follow-up (P<0.0001; n=54), whereas 
serum APRIL levels decreased (P=0.008; n=54). 
 
4.2.3 Response rates 
 
Forty patients (78.4%; n=51) attained SRI response during follow-up, after a median time of 
3.5 months. Thirty-eight patients (66.7%) attained LLDAS after a median time of 7.5 months. 
Thirty-two patients (56.1%) attained an mSLEDAI-2K score of 0 after a median time of 9.1 
months (Figure 4.4). 
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4.2.4 Baseline predictors of SRI response 
 
 
A baseline SLEDAI-2K score of ≥10 (HR: 2.553; 95% CI: 1.339–4.896) and high baseline 
prednisone equivalent dosages (HR: 1.029; 95% CI 1.003–1.056) predicted increased 
probability and shorter time to attain SRI response (Figure 4.4).  
Baseline SDI scores >1 predicted decreased probability and prolonged time to attain SRI 
response (HR: 0.449; 95% CI: 0.208–0.967). In contrast, SLE disease duration was not found 
to impact the treatment outcome (HR: 0.973; 95% CI: 0.931–1.017) (Figure 4.4). Venous 
thrombosis prior to treatment initiation was the only one among SDI items to predict reduced 
efficacy of belimumab in inducing SRI response (HR: 0.184; 95% CI: 0.043–0.784). This 
finding remained statistically significant after adjustment for SLE disease duration (HR: 
0.184; 95% CI: 0.043–0.794). 
Moreover, baseline BLyS levels equal to or higher than the 75th percentile (≥1.2 ng/mL) also 
predicted increased probability and shorter time to attain SRI response (HR: 2.566; 95% CI: 
1.222–5.387) (Figure 4.4). 
 
4.2.4.1 Effects of smoking on the efficacy of belimumab 
 
After adjustment for baseline SLEDAI-2K scores and prednisone equivalent dosages, current 
tobacco smokers showed a decreased probability and prolonged time to attain SRI response 
compared with former and never smokers (HR: 0.103; 95% CI: 0.025–0.427). This finding 
was still significant after adjustment for concomitant use of antimalarial agents (HR: 0.109; 
95% CI: 0.026–0.464). Ever smokers also showed a lower probability and prolonged time to 
attain SRI response compared with never smokers (HR: 0.460; 95% CI: 0.223–0.951), which 
remained significant after adjustment for concomitant use of antimalarial agents (HR: 0.477; 
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Figure 4.4. Response rates and baseline predictors of treatment response 
Graph A illustrates response rates over time during treatment with belimumab according to 
SRI, LLDAS and mSLEDAI-2K=0. Box plots in graph B depict the time from baseline to 
SRI response, LLDAS and mSLEDAI-2K=0 in patients who attained the respective outcome. 
Lines in the boxes denote medians, bounds denote quartiles, and whiskers denote ranges. 
Graph C shows results from univariate and multivariate Cox regression models for evaluation 
of baseline variables as predictors of response to treatment. Vertical lines group variables 
analysed together in multivariate models.  
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4.2.5 Patient-reported outcomes 
 
According to self-reports, patients improved during follow-up regarding pain (P<0.0001), 
fatigue (P=0.007), general health (P<0.0001), EQ-5D (P=0.008), and HAQ (P=0.014). The 
observed decrease in pain remained significant after adjustment for fibromyalgia (P<0.0001). 
 
4.2.6 Drug discontinuation and adverse events 
 
Of 58 patients, 39 patients (67.2%) were still on treatment at the end of the follow-up. 
Belimumab treatment was discontinued in 19 patients, after a median time of 8.3 months. In 
12 of these 19 patients, belimumab was discontinued due to inadequate effect or flare, in four 
patients due to adverse events (Table 4.6), and in three patients due to pregnancy plans. 
 
Table 4.6. Adverse events and flares during follow-up 
Adverse events Number Discontinuation 
Total 29 - 
Patients with at least one adverse event 19 - 
Infections 9 - 
Pneumonia 4 No 
Tooth infection 2 No 
External otitis 1 No 
Herpes zoster infection 1 No 
Other skin infection 1 No 
Allergic reactions  2 Yes 
Headache during or following infusions 4 No 
Malaise 3 No 
Exanthema 2 Yes, n=1; No, n=1 
Pain   2 Yes, n=1; No, n=1 
Nausea 1 No 
Syncope 1 No 
Angioedema (eyelids, tongue) 1 No 
Anxiety   1 No 
Arrhythmia   1 Yes 
Depression   1 No 
Insomnia   1 Yes 
Malignancies  1 Yes 
Deaths 0 N/A 
Flares Number Discontinuation 
LN ISN/RPS class IV S A; de novo 1 Yes 
Neuropsychiatric SLE 2 Yes 
Arthritis 1 Yes 
Mucocutaneous manifestations 1 Yes 
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4.2.7 B cell alterations 
 
In Paper V, peripheral blood samples captured on three to six occasions from 23 SLE 
patients treated with belimumab were analysed using mass cytometry. From the dataset 
generated, we focused on CD20+ B cells, and following t-SNE dimensionality reduction into 
two-dimensional space, we clustered cells with similar phenotypes in an unbiased manner. 
The patient samples comprised considerably more differentiated B cells compared to the 
sample from a healthy blood donor (Figure 4.5). 
 
Figure 4.5. Distributions of naïve and memory B cells  
Distributions of naïve (purple) and memory (green) B cells in SLE patients and a healthy 
control are delineated on t-distributed stochastic neighbour embedding (t-SNE) plots. For the 
SLE patients, 100 B cells per sample are plotted, and all follow-up samples are included. 
 
Some B cell clusters from the t-SNE plots appeared to be overrepresented and even unique 
for the SLE samples. One of these was characterised by a predominant CD11c expression and 
most probably corresponds to the B cell subtype designated as age-associated B cells [427, 
428], as it lacked CD21 expression. Furthermore, a novel subset was characterised by 
expression of CD57, a terminal differentiation marker in the context of T cells [429-431] and 
NK cells [432]. In the sample from the healthy control, these CD57+ B cells did not form a 
distinct cluster. We used flow cytometry to confirm this B cell phenotype and observed a 
small but distinct CD57+ B cell cluster, as well as a clear enrichment of CD57+ non-B cells, 
CD
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in SLE peripheral blood. Even in this analysis, this B cell cluster was absent in a healthy 
blood donor. Another small but distinct and novel B cell cluster co-expressed CD14 and 
CD11c (Figure 4.6).  
 
 
Figure 4.6. Novel B cell subsets  
Novel B cell subsets are depicted on a t-distributed stochastic neighbour embedding (t-SNE) 
plot. A predominant CD57 and CD11c expression is apparent in distinct clusters (upper right 
and upper left). The CD57+ subset is absent in the healthy control. 
 
We observed a consistent overall decrease of B cells, which replicates the observations from 
the clinical trials [399, 414]. At month three, significant decreases were observed for 
IgM+IgD+CD27- naïve (P=1·10-13) and CD11c+CD21- age-associated (P=8·10-7) B cells, 
whereas IgD+CD27+ pre-switching (P=0.052) and IgM+IgD-CD27- double-negative 
(P=0.033) memory B cells showed a more modest decline, which occurred at later time 
points. The CD57+ B cell subset showed a continuous decrease over time (P=0.004). In 
contrast, switched memory B cells showed an initial increase at month three with a 
subsequent return to baseline values. Despite their scarcity in peripheral blood, we also 
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investigated CD19+CD38+CD27+CD20- plasma cells, which showed no significant alterations 
(P=0.72). Finally, we observed no significant changes in CD14+CD20-CD3e- monocytes 
(P=0.73), CD3e+CD4+CD20- helper T cells (p=0.45), or CD3e+CD4-CD20- cytotoxic T cells 
(P=0.22).  
Next, we explored the correlation between individual cell surface antigens and time on 
treatment, divided into early (months 0–3), intermediate (months 3–6), and late (months 6–
36) time intervals. Cell surface antigen expression alterations were distinctly different 
between the three time intervals. Several surface antigens were affected by treatment during 
early time points, showing moderate to strong correlations with time, while only a few 
markers showed changes in the later time intervals.  
Since changes in antigen expression over time might, in several cases, represent a phenotypic 
alteration within a cell type rather than transition into another cell type, we next sought to 
identify marker combinations representing B cell subtypes. We did this in two ways. The first 
approach was hierarchical clustering based on expression level. In the second approach, we 
created heat maps illustrating time correlations for pairs of markers in order to identify cell 
subsets being altered in numbers over time. Decreasing numbers of naïve B cells were 
visualised as a clustering of IgM and IgD at both early (months 0–3) and intermediate 
(months 3–6) time points. In the individual marker analysis, CD38 displayed an increase 
during late time points, despite an initial decrease during months 0–3. We further explored 
this in the pair analysis, and while CD38 was strongly co-expressed with CD21 and CD22 at 
early time points, it showed a mutually exclusive expression pattern with CD21 and CD22 at 
later time points. Thus, the early decrease of CD38 presumably corresponds to the changes in 
naïve B cells, and the late increase corresponds to a novel CD38+IgM+IgD+CD22-CD21-
CD27- B cell subtype, which was found to be resistant to belimumab treatment.  
Overall, these results delineate a stepwise change in the B cell composition during 
belimumab treatment, with less differentiated cell types being affected early, possibly 
resulting in cascade effects on cell subtypes of later stages that decrease subsequently.  
Combining unbiased and targeted approaches, we were able to distinguish changes in cell 
phenotypes from cell subset alterations. During months 3–6, CD57 and CD11c showed 
moderate increases. However, the CD57+CD11c+ cluster observed in t-SNE displayed a 
decrease during months 3–6, and CD57 and CD11c were not found to be co-expressed on the 
same cells at either early or later time points, implying a relative increase in the expression of 
these markers rather than numerical alterations in the CD57+CD11c+ B cell cluster. 
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4.2.8 B cell alterations and SLE disease activity 
 
In order to investigate B cell alterations in the context of SLE disease activity, we repeated 
the correlation analysis of individual markers, this time with SLEDAI-2K scores [185] 
normalised for baseline values. Disease activity showed a rapid early and a continuous 
gradual decrease during follow-up. Early immunologic changes were correlated with clinical 
improvements, but no correlation was seen during the later time points. Interestingly, despite 
only moderate alterations in CD11c expression during months 0–3, decreasing CD11c 
expression correlated with decreasing SLEDAI-2K scores. 
Concurrently with decreasing SLEDAI-2K and decreasing early stage B cell surface antigens, 
levels of anti-dsDNA also decreased at early, but not at later time points. The changes in anti-
dsDNA levels also correlated with the immunologic changes observed at early time points.  
 
4.2.9 B cell alterations and clinical response to treatment 
 
In addition to disease activity, we analysed the observed changes in cell subsets in relation to 
clinical response to treatment. It is worth noting that essentially all patients responded to 
treatment immunologically; e.g. all but one patient showed immediate reductions in naïve B 
cells.  
Of the 23 patients, 19 patients attained SRI response during follow-up, after a median time of 
3.6 months. LLDAS was attained in 18 of 23 patients, after a median time of 12.0 months, 
and at month 24, 11 of the 17 patients who still were on treatment had a low activity state. 
We observed lower baseline B cell counts in patients who attained LLDAS at month 24 
compared to patients who did not (P=0.003), whereas baseline total lymphocyte counts did 
not differ between the two groups (P=0.301). By ROC-curve analysis, higher baseline B cell 
counts were predictive of non-attaining LLDAS at month 24, with an AUC of 94.5% (95% 
CI: 0.830–1.00). The optimal threshold value was found to be 155 cells/µL, and yielded a 
specificity of 90.9% and a sensitivity of 100% for predicting failure to attain LLDAS through 
month 24. The respective AUC for baseline lymphocyte counts was 66.7% (95% CI: 0.388–
0.946).  
Interestingly, age-associated B cells were found to rapidly decrease and remain low in early 
responders, whereas they decreased more gradually in late responders and were resistant to 
change in non-responders. This pattern was absent in the same analysis for total B cell counts. 
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5 DISCUSSION 
 
5.1 BIOMARKER STUDIES 
 
In Paper I, Paper II and Paper III, we evaluated autoantibodies and cytokines in lupus 
nephritis, in order to contribute to the understanding of their role in the disease. We further 
assessed these molecules as candidate biomarkers of treatment response and long-term renal 
prognosis.  
 
5.1.1 aPL and short-term renal outcomes in LN 
 
In Paper I, we investigated the impact of antiphospholipid antibodies on short-term and long-
term renal outcomes in patients with active biopsy-proven LN, without a concurrent APLN. 
Results from previous studies of aPL in LN have been conflicting [408, 433]. We found no 
association between aPL positivity or serum aPL levels and LN, suggesting that aPL per se 
are not associated with the occurrence of LN. However, we found an association between 
definitely diagnosed APS and LN. This is an important finding considering that aPL-positive 
individuals do not always develop symptoms [233, 234], and those who develop symptoms 
are likely carriers of more pathogenic aPL. 
In accordance with previous studies [407, 434], we found no correlation between aPL and 
either activity or chronicity features in renal biopsies. However, we found higher creatinine 
levels in LN patients with IgG aPL compared to patients without, both at active disease and 
post-treatment, suggesting that IgG aPL may affect the renal function during a LN flare, 
despite the absence of histological findings consistent with APLN. The reason for this is 
unclear, and surveys of aPL expression in renal tissue are needed in order to clarify their 
pathogenic role. In a recent study, the renal vascular expression of annexin A2, a 
phospholipid-binding protein [435] with an important role in the pathogenesis of APS [436-
439] and LN [440], did not differ between patients with LN and patients with other kidney 
diseases. Interestingly, however, annexin A2 expression was more intense in patients with 
vascular changes consistent with APLN [441].  
An interesting finding was that aPL levels decreased in LN patients who responded to 
treatment, including patients with baseline aPL levels below the cut-off value for positivity, 
but remained stable in non-responding patients. In contrast, anti-dsDNA levels decreased 
regardless of the treatment outcome. This implies that the decreases in aPL levels were 
unlikely due to a general effect of immunosuppression on Ig levels, which was also supported 
by the decreasing ratios of IgG aPL to total IgG levels. Based on these findings, the 
occurrence of IgG aPL may be hypothesised to reflect and possibly contribute to a more 
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severe LN phenotype. However, it is important to underline that the clinical significance of 
aPL levels below the cut-off value for positivity is questionable. For this reason, our 
investigation in Paper I included both aPL levels and positivity.   
While previous studies have consistently demonstrated associations of aCL [247, 248], anti-
β2-GPI [250], and LA [246, 250] with APS nephropathy, as well as associations between 
APS nephropathy and the development of ESRD [248], surveys of the impact of aPL on renal 
outcomes in patients with LN have been conflicting. A study found an association of aPL 
with renal function deterioration [406], another study found no association with long-term 
renal outcomes [407], and, recently, even a protective role of IgM anti-β2-GPI against renal 
damage was documented [408]. In our study, we were able to confirm an association of IgG 
aPL with renal function impairment in a short-term perspective, but we found no protective 
role of IgM anti-β2-GPI against renal activity or damage.  
 
5.1.2 aPL and long-term renal outcomes in LN 
 
We found no association between aPL positivity or serum levels of aPL and renal function 
deterioration in the long term. This indicates that aPL per se may not contribute to a poor 
long-term renal prognosis in patients with LN in the absence of APLN. Supportive of this 
hypothesis was also a recent study comprising 349 SLE patients, which demonstrated that 
antiphospholipid antibodies were not predictive of irreversible renal damage [442], as 
assessed using the SDI [196]. However, no firm conclusions regarding the impact of aPL on 
the long-term renal outcome can be drawn from our study due to the sample size and the 
limited proportion of aPL-positive patients in the prospective LN cohort.  
 
5.1.3 The role of TNFR2 in LN  
 
In Paper II, we investigated the performance of sTNFR2 as a biomarker of renal activity and 
damage, treatment response, and long-term outcome in LN. Circulating levels of sTNFR1 
and sTNFR2 are usually correlated both with each other and with TNF-α [274, 443], but they 
have distinct roles both in immune responses in general and in kidney diseases [257, 258]. 
While TNFR1 is found in healthy renal tissue, TNF-α and TNFR2 are usually absent [444]. 
During inflammation, however, TNFR2 is expressed both in glomerular and tubular cells 
[444, 445], and, in murine experiments, renal expression of TNFR2 (but not TNFR1) was 
essential for the development of IC-mediated glomerulonephritis [446], contributing to the 
rationale for studying TNFR2 in LN. 
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In a recent study, sTNFR1 and sTNFR2 levels were higher in SLE patients compared to 
healthy controls, and sTNFR2 levels were also higher in patients with active LN than in 
patients with quiescent SLE [295]. Another study found elevated levels of sTNFR2 in 
patients with LN compared to non-renal SLE patients [270]. Recently, sTNFR2 levels were 
found to be associated with impaired renal function and proteinuria in juvenile-onset SLE 
[443]. In accordance with another study comprising thirteen patients with LN [266], we 
observed reductions in sTNFR2 levels following treatment. However, we found no 
association between sTNFR2 and global SLE disease activity, suggesting a particular role of 
TNFR2 in LN. We conducted no immunohistochemistry experiments, but the increased 
serum sTNFR2 levels during active LN may reflect increased expression of TNFR2 in the 
kidney. Supportive of this is a previous study of 113 patients with idiopathic membranous 
nephropathy [277], in which TNFR2 expression, predominantly seen in tubules and scarcely 
in glomeruli, was higher in patients with high versus low circulating sTNFR2 levels.  
In the combined LN patient cohort and in the proliferative LN subgroup, sTNFR2 levels 
decreased regardless of the treatment outcome. In contrast, in the membranous LN subgroup 
sTNFR2 levels decreased only in clinical responders, and higher baseline levels predicted 
both clinical and histological response to treatment. Although validation is needed 
considering the low number of patients in the membranous LN subgroup, our results are 
indicative of different roles of TNFR2 in proliferative versus membranous LN. 
The most striking finding of Paper II was that sTNFR2 correlated with renal damage, both at 
baseline and post-treatment, and was associated with increasing Chronicity Index scores in 
renal biopsies. Consistently, both baseline and post-treatment sTNFR2 levels were found to 
be associated with renal function deterioration in the long term, suggesting that sTNFR2 
levels may mirror chronic changes in the kidney tissue and portend renal damage accrual. 
Post-treatment proteinuria was recently demonstrated to be a powerful predictor of the long-
term renal outcome in LN [447, 448]. In the light of this, our finding that sTNFR2 correlated 
with proteinuria post-treatment also support the notion that sTNFR2 levels may be a potential 
predictor of the long-term outcome in LN. Our finding is also consistent with results from a 
study of idiopathic membranous nephropathy, which found that high sTNFR2 levels at the 
time of diagnosis were associated with renal function deterioration over time [277]. 
The associations of high sTNFR2 levels with renal damage and poor long-term renal 
outcome, together with the observation that higher baseline levels predicted favourable 
treatment outcomes in membranous LN, constitute a paradox, since responding patients may 
be expected to have a better long-term prognosis compared with non-responders. A possible 
explanation might be that patients with high sTNFR2 levels represent a LN subset with a 
more severe disease phenotype, in which induction therapy may be efficacious in reducing 
renal disease activity in the short term, but fail to prevent long-term damage progression. 
Whether the observed association between sTNFR2 levels and long-term renal function 
impairment reflected an accumulation of sTNFR2 due to glomerular hypofiltration or renal 
TNFR2 overexpression and subsequent injury remains to be elucidated. The assumption that 
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the degree of proteinuria may have influenced the estimated circulating sTNFR2 levels due to 
clearance in urinary losses is rather unlikely, as there was no inverse correlation between 
sTNFR2 levels and levels of proteinuria. Further investigation of TNFR2 in renal tissue and 
urinary losses might be useful in order to clarify the mechanisms underlying our 
observations.  
MCP-1 has been shown to contribute to the recruitment of inflammatory cells and 
tubulointerstitial damage in LN [449, 450], and it has also been shown to be predictive of 
poor renal prognosis in paediatric LN [165]. This was further explored in a recent study, in 
which TNF-α effectively stimulated podocytes to produce MCP-1 [451]. Interestingly, 
TNFR2 was shown to be essential for mediating this effect of TNF-α on MCP-1 production 
[451]. Being the link between TNF-α and MCP-1 production by podocytes, and also a 
mediator of glomerular complement deposition [446], TNFR2 emerges as a key player in 
renal injury and damage, yet the causes of its overexpression in renal tissue remain unclear.  
Based on our observation that post-treatment sTNFR2 levels were higher in patients with a 
poorer long-term renal outcome, modulation of the TNF pathway might be considered a 
potential option for the treatment of LN. Previously, short-term TNF-α inhibition with 
infliximab combined with background immunosuppression was shown to reduce proteinuria 
levels [452] and induce long-term remission in patients with refractory LN, but prolonged 
administration led to severe adverse events [453-455]. In another study, long-term therapy 
with etanercept (a fusion protein containing sTNFR2) in addition to background 
immunosuppression had a more favourable safety profile and promising long-term efficacy in 
patients with refractory lupus arthritis [456]. Although TNF-α inhibition remains a 
controversial option for SLE, alternative ways to modulate this pathway, e.g. through specific 
inhibition of TNFR2, has previously been suggested [258] and might prove useful in the 
future. Supportive of more targeted inhibition was also a study of murine lupus, in which 
double deficiency of TNFR1 and TNFR2 was highly deleterious resulting in accelerated 
nephritis features, but deficiency of only one receptor did not have such effects [269]. 
 
5.1.4 The role of BLyS in LN 
 
In Paper III, serum levels of both BLyS and APRIL were found to be higher in patients with 
active LN compared to controls at baseline, but they were affected differently by 
immunosuppression; BLyS concentrations remained unchanged following therapy, whereas 
APRIL levels decreased. Low baseline BLyS levels predicted treatment response, both 
according to clinical features and histological findings. 
BLyS has been shown to be overexpressed in patients with SLE and other rheumatic diseases 
[308-311]. BLyS levels have also been demonstrated to correlate with SLE disease activity 
and anti-dsDNA titres [311, 312]. Anti-dsDNA antibodies are known to correlate with SLE 
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disease activity, especially in patients with renal involvement [71, 89, 457-459]. In our study 
of LN, we found higher levels of BLyS in patients compared to controls, but no correlation 
with anti-dsDNA levels or SLEDAI-2K scores could be confirmed. As expected, decreases in 
both anti-dsDNA and anti-C1q antibodies were documented following treatment, but these 
decreases were seen regardless of the clinical or histological treatment outcome; therefore, 
the role of these autoantibodies as biomarkers of treatment response is rather questionable. 
Contrary to anti-dsDNA and anti-C1q autoantibodies, BLyS levels were unchanged following 
immunosuppressive treatment but low baseline levels predicted favourable treatment 
outcomes.  
Like with sTNFR2 in Paper II, a concern is that the degree of proteinuria might have 
influenced the serum levels of BLyS due to a substantial clearance in urinary losses, and 
patients with low levels of BLyS may actually represent a subset of patients with high 
proteinuria levels [460]. However, we observed no inverse correlation between BLyS levels 
and proteinuria, suggesting that such interference is rather unlikely.  
BLyS is a well-characterised B cell maturation and survival factor, which can be produced by 
many different cell types [299]. Our study was not designed to deduce whether the 
distribution of BLyS producing cells differed in patients with low versus high serum levels of 
BLyS. However, our findings might inspire future investigations in that direction. A type I 
IFN signature is often observed in SLE, and it is known to trigger BLyS production; thus, it is 
tempting to speculate that plasmacytoid dendritic cells might be involved [323], and patients 
with low BLyS levels may hence be hypothesised to have a weaker type I IFN signature. 
Patients in whom a full feedback loop in B cell dysregulation is absent may hypothetically 
represent a patient subset that would be more sensitive and responsive to immunomodulatory 
treatment. In this context, it is of interest that BLyS inhibition with belimumab has been 
shown to alter the numbers and the distribution of B cell subsets [399], which we further 
explored in Paper V.  
A longitudinal study of rituximab-treated patients with SLE found that BLyS levels increased 
during B cell depletion, followed by a gradual return to pretreatment levels towards B cell 
repopulation [322]. A similar pattern was observed in rituximab-treated patients with 
rheumatoid arthritis [461] and primary Sjögren’s syndrome [462]. In our study, BLyS levels 
were unchanged following treatment. However, we assessed BLyS levels on only two 
occasions, prior to and after completion of induction therapy, and with unknown status of B 
cell depletion. It is noteworthy that patients treated with rituximab and/or cyclophosphamide, 
both B cell depleting therapies, showed significantly higher BLyS levels post-treatment 
compared to patients treated with mycophenolate mofetil, in whom both B cells and T cells 
are expected to be downregulated, indicating that these respective therapeutic strategies affect 
serum BLyS differently. 
The maintenance of BLyS levels post-treatment is supported by previous findings of BLyS 
being constitutively produced by stromal cells [298, 463]. Additionally, as previously 
suggested [464, 465], the observed excess of BLyS in patients with SLE might have a 
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contributive role in the survival of autoreactive B cells. Moreover, BLyS has been shown to 
have a central role in the survival of plasmablasts and plasma cells, and plasma cell 
frequencies have been shown to correlate with SLE disease activity [301, 398, 400, 466]. 
Thus, the stable excess of BLyS in patients with LN might contribute to irresponsiveness to 
treatment or higher risk for flare. Indeed, a previous study demonstrated that high baseline 
BLyS levels in patients with refractory SLE, 18 of 25 with renal involvement, were 
associated with a shorter time to flare following B cell depletion [467]. 
Together with the observation of low baseline BLyS levels being predictive of favourable 
treatment outcomes, our findings support previous suggestions that BLyS neutralisation 
accompanying conventional immunosuppression might be an efficient therapeutic approach 
[322, 461]. A post-hoc analysis from the phase III RCTs of belimumab implicated greater 
efficacy of belimumab in renal outcomes as an add-on to standard treatment compared to 
standard treatment alone [397]. Results from ongoing LN trials of BLyS inhibition, as well as 
a LN trial of B cell depletion combined with BLyS inhibition, are anticipated. 
 
5.1.5 The role of APRIL in LN 
 
Serum levels of APRIL have previously been shown to correlate with renal disease activity in 
patients with LN, and high APRIL levels have been demonstrated to predict treatment failure 
[468]. In accordance with these findings, we observed initially high APRIL levels compared 
to controls, which decreased following therapy. Interestingly, no decrease was seen in either 
clinical or histological non-responders within the proliferative LN subgroup. This suggests 
that APRIL might be a useful biomarker of renal disease activity in patients with proliferative 
glomerulonephritis and indicates that the regulation of APRIL might be of importance for 
treatment response in this patient subset. This pattern was not seen in patients with 
membranous LN. Supportive of this discrepancy between proliferative and membranous LN 
regarding the regulation of APRIL was also a previous study that documented a prominent 
glomerular expression of APRIL in proliferative but not in membranous nephritis [314].  
The potential of APRIL activity modulation has recently been discussed [468], and atacicept 
has been tested for LN. The trial was terminated, as three of the first four patients assigned to 
receive atacicept developed hypogammaglobulinemia and two patients developed severe 
pneumonia [362]. However, our findings merit further investigation of APRIL activity 
manipulation in patients with proliferative LN.  
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5.2 STUDIES OF BELIMUMAB 
 
5.2.1 Clinical effects 
 
5.2.1.1 Effects on SLE disease activity 
 
In Paper IV, we investigated the clinical and serologic effects of belimumab treatment in 58 
patients with SLE. In agreement with the RCTs of belimumab [201, 202] and recent 
observational studies [469-472], we observed decreasing disease activity during follow-up, 
corresponding to changes greater than the minimal clinically important differences (MCIDs) 
proposed for SLEDAI-2K and SLAM-R [473] already at month three. In accordance with 
previous implications [474], we also found decreasing corticosteroid use, indicating steroid-
sparing effects of belimumab. 
Post-hoc analyses from the RCTs have shown that patients with LN might benefit from 
belimumab [397]. In our study, we observed decreasing proteinuria and improved renal 
activity according to the renal components of the SLEDAI-2K, and renal activity at baseline 
showed a trend of predicting SRI response. By contrast, one patient with no prior history of 
nephritis developed a de novo LN during the observation period [475]. Hence, further 
investigation of belimumab in LN is needed in order to determine its role in the treatment of 
this SLE subset. 
 
5.2.1.2 Smoking predicted reduced efficacy 
 
One of the most striking findings in Paper IV was that smokers had a decreased probability 
and prolonged time to respond to the treatment. This finding is in line with previous reports 
of smoking reducing the efficacy of antimalarial agents in cutaneous SLE [476], as well as 
the efficacy of methotrexate and TNF inhibitors in rheumatoid arthritis [477, 478]. Among 
possible explanations, it has recently been hypothesised that smoking may induce the 
production of neutralising anti-drug antibodies, with the lungs playing an important role as 
immune-reactive organs [479, 480]. It is known that smoking in SLE patients is associated 
with increased disease activity and damage accrual [481, 482]. Interestingly, the association 
between smoking and decreased efficacy of belimumab in our study was revealed only after 
adjustment for baseline disease activity and corticosteroid dose, and remained significant 
after adjustment for concomitant use of antimalarial agents. Our findings suggest that current 
smokers who qualify for treatment with belimumab should be encouraged to quit smoking. 
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5.2.1.3 Established damage predicted reduced efficacy 
 
We observed no significant organ damage progression during follow-up. In SLE, patients 
with damage represent a group with a more severe phenotype and an unfavourable prognosis 
[483, 484]. In our study, established damage at baseline was shown to predict decreased 
efficacy of belimumab, with previous venous thrombosis being of particular importance. It is 
worth noting that disease duration was not found to confound this finding. Whether SLE 
patients with a concomitant antiphospholipid syndrome are less likely to respond to 
belimumab treatment remains to be elucidated.  
 
5.2.1.4 High baseline BLyS levels predicted beneficial treatment outcomes 
 
High baseline serum BLyS levels were predictive of increased likelihood and shorter time to 
attain SRI response to belimumab. This is an important finding considering that patients with 
high BLyS levels have a higher risk for flares when only standard of care therapy is given, 
based on data from the RCTs of belimumab [485]. Consistent with our finding was a recent 
study showing better clinical outcomes in SLE patients with high baseline BLyS levels 
treated with the BLyS and APRIL inhibitor atacicept compared to patients who had received 
placebo, which was not the case in patients with low BLyS levels [486].  
This finding of Paper IV might be expected considering the mechanism of action of 
belimumab. In Paper III, where the treatment regimens used to induce renal remission were 
therapies causing a non-specific immunosuppression, with the exception of rituximab in 
seven patients, low baseline BLyS levels were found to be predictive of favourable treatment 
outcomes and patients with high BLyS levels showed a more varying response pattern. In the 
light of our later finding in Paper IV, it is tempting to speculate that addition of BLyS 
inhibition in the LN patients with high baseline BLyS levels might have improved the 
treatment outcomes. 
In Paper IV, BLyS levels were found to increase during treatment with belimumab, which is 
opposed to the mechanism of action of this antibody. The reason for this phenomenon is 
unclear. A possible explanation might be that belimumab and soluble BLyS are organised in 
immune complexes, preventing the binding of BLyS to its cell membrane receptors and 
diminishing its renal elimination. This might result in a new steady-state level of presumably 
biologically inactive circulating BLyS, as previously demonstrated for IL-6 during anti-IL-6 
therapy [487] and for TNF-α during anti-TNF-α therapy [488]. Other or synergistic 
mechanisms explaining this ostensible paradox may include a soluble BLyS excess due to the 
expected decrease of B cell counts [200, 202, 399, 414], its main consumers [301], and a 
reactive increase of BLyS production, as previously shown following B cell depleting 
therapies [322].  
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In contrast, serum levels of APRIL decreased over time despite the anticipated decrease of 
activated B cells and plasma cells [200, 202, 399], which are known to express receptors for 
APRIL [489-491]. As belimumab is not expected to neutralise serum APRIL levels by 
directly binding to APRIL, it could be hypothesised that APRIL is consumed on the two 
receptors it has in common with BLyS on the surface of B cells [303, 304], in the absence of 
the interference of BLyS. Moreover, in our longitudinal observations in Paper V we could 
not confirm the previously observed decreases in plasma cells.  
Further, we followed patient-reported outcomes. To our knowledge, this is the first report on 
improved pain, general health, global health and functional status. Improvements in fatigue 
have been reported in a post-hoc analysis of data from the clinical trials [340]. In our cohort, 
the patient-reported changes in fatigue reached the MCID proposed for fatigue VAS [473] at 
month 18. These findings contribute to the discussion on the value of belimumab from the 
perspective of cost-effectiveness. Finally, the safety profile of belimumab in our study was 
acceptable, and comparable with previous reports [200-202, 492]. 
 
5.2.2 Immunologic effects 
 
In Paper V, we investigated alterations in leucocyte populations and subsets during treatment 
with belimumab in 23 patients with SLE using mass cytometry (CyTOF).  
The SLE patients in our cohort were shown to have a distinctly different B cell profile 
compared to a healthy control, with a larger fraction of memory B cells and pronounced cell 
differentiation. These differences became more prominent following treatment, as belimumab 
had rapid deleterious effects on naïve B cells and B cells of earlier developmental stages 
while later stage B cells were more resilient to alterations and were only affected at later time 
points. 
The combination of mass cytometry data and longitudinal clinical assessments using 
validated measures enabled us to analyse immunologic changes during BAFF inhibition not 
only in relation to SLE disease activity, but also to well-defined clinical outcomes. We 
combined unbiased with hypothesis-based approaches to analyse the data, and identified both 
novel B cell subsets and B cell subsets associated to the treatment outcome. 
 
5.2.2.1 Rapid decreases in naïve and age-associated B cells 
 
Belimumab treatment has previously been shown to reduce the numbers of CD20+ B cells 
and not affect the T cells [202, 399, 414]. Naïve and double-negative memory B cells have 
been reported to continuously decrease in numbers [399, 414], whereas pre-switching 
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memory B cells and plasmablasts have been shown to decrease at later time points [414]. A 
study has demonstrated preservations of pre-existing antibodies to pneumococcal and tetanus 
vaccines, but decreasing plasma cell numbers [399]. We similarly observed a rapid decrease 
in naïve B cells, a gradual decrease in double-negative and a trend towards a decrease in pre-
switching memory B cells, and no significant impact of belimumab on T cells. In contrast, we 
found no significant changes in plasma cell numbers. 
The rationale of B cell depletion has received increasing recognition during the last years, yet 
the resistance of long-lived plasma cells to current therapies targeting the B cells remains a 
concern [493, 494]. The use of rituximab in SLE has increased during the last years, but 
despite resulting in a profound B cell depletion, rituximab treatment is not expected to have 
immediate effects on mature plasma cells, the main source of circulating IgG. According to 
our results, BAFF inhibition with belimumab had no significant effects on plasma cells either. 
In the light of this, investigation of proteasome inhibition in SLE might be of interest. 
Through blocking the anti-apoptotic nuclear factor kappa B (NF-κB) activation, proteasome 
inhibition causes accumulation of misfolded proteins within the endoplasmic reticulum, 
resulting in apoptosis [495-497]. In murine lupus, proteasome inhibition with bortezomib has 
been demonstrated to improve nephritis features [498] while the proteasome inhibitors 
delanzomib and carfilzomib have been shown to reduce autoantibody levels and type I IFN 
production [499, 500]. Interestingly, bortezomib, approved for the treatment of multiple 
myeloma, was recently shown to improve the disease activity and effectively reduce the 
numbers of peripheral blood and bone marrow plasma cells in a limited number of refractory 
SLE patients [339]. 
As shown in previous studies [200, 399], in Paper V we observed an initial expansion of 
switched memory B cells at month 3 with a subsequent return to baseline values. While the 
preservation of memory B cells was expected, as their survival is not BLyS-dependent [401], 
the mechanism underlying their early increase is unclear. The direct effects of belimumab on 
B cells of earlier stages might have a contributing role, e.g. resulting in disruptions of 
germinal centres and release of memory B cells residing therein.  
Age-associated B cells constitute a recently described B cell subset, characterised by a 
gradual accumulation with age, in chronic inflammatory diseases, or following repeated viral 
infections [427, 428]. In Paper V, we observed decreases in numbers of this cell subset 
already at early time points, with continuous gradual decreases over time, which is consistent 
with previous reports of age-associated B cells expressing cell surface receptors for BLyS 
[428]. Interestingly, age-associated B cells were differently affected in different patients 
depending on the clinical outcome, showing an early and continuous decrease following 
treatment in early responders, but being more resistant to change in non-responding patients 
and patients with delayed clinical improvements. Indeed, although they express receptors for 
BLyS, the survival of age-associated B cells has been shown to be independent of BLyS 
[428], and the discrepancy in how they were affected by belimumab in early, late and non-
responders might therefore reflect the grade of inflammation rather than a direct impact of 
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belimumab through blocking BLyS. Consistently, we could demonstrate that clinical 
improvements positively correlated with decreasing CD11c immediately following treatment 
initiation.  
 
5.2.2.2 Identification of novel B cell subtypes 
 
The unbiased t-SNE and hierarchical clustering revealed cell types that we were unable to 
relate to the literature. We demonstrated a distinct cluster of B cells expressing CD57, a 
marker of final stage differentiation, mostly known in the context of T cells and NK cells 
[429, 430, 432, 501]. In the context of B cells, CD57 expression has, to date, only been 
implicated in specific types of B cell lymphomas [502-505], which together with the findings 
in the current study renders support for a role in disease state. This CD57+ B cell subset was 
found to rapidly decrease following treatment with belimumab, in a manner similar to that of 
age-associated B cells. Knowing that CD57 expression increases with age and chronic 
infections, at least in the context of NK cells [432], this B cell subset might share common 
characteristics with age-associated B cells. 
 
5.2.2.3 Significance for the clinical use of belimumab 
 
B cell alterations occurred in two phases, a rapid early and a more gradual late phase, and 
SLE activity decreased rapidly following treatment initiation and continued to decrease 
during later time points. However, only the early immunologic changes were found to 
correlate with clinical improvements. Thus, improvements observed at later time points might 
reflect preceding immunologic alterations. This might have direct implications in the clinical 
use of belimumab, as early treatment evaluation and discontinuation might result in 
underestimation of delayed clinical effects reflecting B cell changes occurring at later time 
points. It is noteworthy that our results supported implications in the same direction also in 
Paper IV, where treatment response was assessed using three different definitions. SRI 
response was attained earlier and in more patients compared to LLDAS and mSLEDAI-
2K=0, in most cases already at month three, but LLDAS and mSLEDAI-2K=0 were not 
achieved until after a median of 7.5 and 9.1 months, respectively. This suggests that a 
conclusive evaluation of treatment response to belimumab cannot be conducted earlier than 
6–12 months after treatment initiation. 
Referring back to Paper V, high baseline B cell counts were found to predict unfavourable 
treatment outcomes, in contrast to total lymphocyte counts. In clinical praxis, it is common to 
test for lymphocyte counts, but B cell counts are seldom assessed. However, our results 
suggest that evaluation of B cell counts might prove useful prior to initiation of belimumab 
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treatment and favour the notion that B cell depletion preceding BLyS inhibition might be an 
effective therapeutic strategy in cases of high B cell counts, as speculated upon in Paper III 
[171] and in other previous works [322, 461]. 
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5.3 LIMITATIONS AND STRENGTHS 
 
Our studies of LN were limited in power by the size of the patient cohorts, especially 
regarding the membranous LN subgroup, and the use of different therapeutic regimens 
depending on individual judgments by the treating physicians. Different immunosuppressive 
medications prior to induction therapy may have contributed to different cytokine profiles, 
complicating the interpretation of the results, which is a common limitation in observational 
studies. Nevertheless, our LN cohort is, to our knowledge, one of the largest LN cohorts with 
post-treatment renal biopsies, allowing a more reliable evaluation of the response to treatment 
based on both clinical with histological outcomes [172].  
Limitations of Paper IV and Paper V included their observational design, the relatively low 
number of patients, and the lack of a placebo arm to facilitate comparisons. Moreover, 
belimumab is indicated as an add-on drug to standard of care therapy, and the patients were 
on concomitant treatments with other drugs, including corticosteroids, which might have 
contributed to the aberrant leucocyte subset composition of the patients. It is worth noting 
that corticosteroid dosages were actively reduced during treatment with belimumab.  
Major strengths were the prospective acquirement of clinical and laboratory data, the 
consistency of the surveillance methods at the contributing centres, the long observation time, 
and, in Paper V in particular, the unbiased approach in several analyses. Being conducted in 
real-life settings, our studies provide information that cannot be derived from RCTs, which 
may be limited by selection bias. Utilisation of mass cytometry in Paper V facilitated the use 
of a broad antigen panel for B cells, resulting in a deeper understanding of the cell subtype 
alterations occurring during treatment with belimumab and in the identification of B cell 
subsets with novel attributes. 
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5.4 CONCLUDING REMARKS 
 
In Paper I, we found no association of either aPL positivity or levels with the occurrence of 
LN. In patients with LN, IgG aPL may contribute to a short-term impairment of the renal 
function, but no effect on the long-term renal outcome was observed. Furthermore, reductions 
in IgG and IgM aPL levels were noted in LN patients who responded to induction treatment, 
but not in non-responders, indicating that aPL levels are affected by immunosuppressive 
drugs in a response-dependent manner.  
Our observations in Paper II suggest that serum sTNFR2 is a non-invasive marker of kidney 
tissue damage, and a predictor of long-term prognosis in LN. Our data also suggest that 
sTNFR2 is a potential predictor of response to treatment in patients with membranous LN.  
In Paper III, we demonstrated that BLyS and APRIL were affected differently by 
immunosuppression; BLyS levels remained unchanged following therapy while APRIL 
levels decreased. Our data were indicative of a role of APRIL in SLE patients with 
proliferative glomerulonephritis, with serum levels of APRIL possibly reflecting the grade of 
renal disease activity. Moreover, low serum concentrations of BLyS were predictive of 
response to induction treatment in LN, especially in proliferative LN.  
In Paper IV, we demonstrated decreased disease activity and corticosteroid usage and no 
significant damage progression during treatment with belimumab. High disease activity, high 
steroid dose and high BLyS levels at baseline predicted beneficial treatment outcomes, 
whereas smoking and established organ damage predicted reduced and/or delayed efficacy of 
belimumab. Based on our data, smokers who qualify for treatment with belimumab should 
actively be encouraged to quit smoking.  
In Paper V, we demonstrated that belimumab treatment had rapid effects on naïve B cells 
and B cells of earlier developmental stages while B cells of later stages showed delayed or no 
responses. The immunologic changes betided in two distinct phases, a rapid early and a 
gradual later phase, whereas SLE activity showed a continuous decrease. Importantly, our 
data imply that early treatment evaluation and discontinuation might underestimate delayed 
clinical improvements occurring as a consequence of late B cell changes. 
While high BLyS levels predicted clinical improvements in Paper IV, high B cell counts 
predicted unfavourable outcomes in Paper V, implying that patients with high B cell activity 
and, therefore, suppressed BLyS activity may benefit from B cell depletion preceding BLyS 
inhibition. 
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5.5 FUTURE PERSPECTIVES 
 
Our findings merit further investigation of aPL, sTNFR2, BLyS and APRIL in larger LN 
cohorts, in order to determine their expression and functional role at a tissue level. In our 
Karolinska LN cohort, renal tissue has been collected when renal biopsies have been 
performed and stored for future research purposes in a systematic manner. Thorough 
selection of tissue from appropriate renal biopsy occasions is planned in order to continue our 
investigations of these and other molecules of interest using tissue-staining methods. 
Since several molecules have emerged as important in LN, it is of vital importance to further 
investigate possible connections at a mechanistic level, and clarify their role in the 
pathogenesis of LN. Multidimensional analysis of different molecules with significant 
importance in LN has to be conducted in order to identify which ones are independently 
important and which ones are linked with each other. Possibly, a combination of non-invasive 
markers might increase their individual specificity and sensitivity in predicting treatment 
outcomes and long-term prognosis, or in reflecting histological findings. Conceivably, a 
biomarker panel with optimised predictive specificity and sensitivity could be an excellent 
substitute of the renal biopsy, which, to date, still is the gold standard for the assessment of 
LN.  
Further evaluation of sTNFR2 in larger LN cohorts, especially in patients with membranous 
LN, might better clarify its role, and possibly reinvigorate the potential of TNF-α pathway 
modulation in future therapeutic approaches. 
Our results in Paper III support further study of agents targeting BLyS and/or APRIL as a 
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5.6 REFLECTIONS ON ETHICAL CONSIDERATIONS 
 
Written and oral informed consent in accordance with the ethical principles for medical 
research involving human subjects of the declaration of Helsinki was obtained from all 
individuals participating in the studies prior to enrolment. The study protocols were reviewed 
and approved by the regional ethics review board at Karolinska Institutet, and for Paper IV 
also by the regional ethics review boards at Lund University and at Linköping University. 
In Paper I, Paper II and Paper III, post-treatment renal biopsies were performed as a part of 
the evaluation of the induction therapy. This has enhanced the strength of these studies. The 
follow-up biopsies introduced a unique possibility to determine the histological outcome 
following immunosuppressive treatment, and therefore facilitated a more reliable evaluation 
of the treatment response. However, renal biopsies may lead to complications, such as pain, 
infections, and bleeding at the site of the biopsy. We were therefore confronted with a 
profound debate on whether performing post-treatment renal biopsies in patients who had 
demonstrated favourable clinical responses was appropriate from an ethical perspective. To 
answer this question, it is important to know whether the histopathology provides the 
physician with additional information needed for the evaluation of the treatment received and 
the choice of continuous treatment. Moreover, it is important to investigate the incidence and 
consequences of the complications during and following renal biopsies. 
The importance of histology in the evaluation of treatment response has been highlighted in a 
study showing an apparent discrepancy between clinical and histological outcome [172], 
supporting that renal biopsies are important for the treatment evaluation and the choice of 
future treatment strategies. In the lupus nephritis cohort of Paper I, Paper II and Paper III, 
adverse events following renal biopsies were minor and few [171]. Of 127 renal biopsies 
performed, only four led to an ultrasound-verified bleeding. In eleven cases, the patient 
experienced pain at the biopsy site, which was manageable in all cases. No infections 
following the renal biopsies were documented. 
Thus, renal biopsies provide important information that may guide the judgement of the 
treating physician, and when the biopsies are performed by skilled personnel under the 
guidance of ultrasonography adverse events are expected to be limited both in terms of 
intensity and frequency. However, the ethical consideration remains, and in patients with risk 
factors for any of the complications described in the literature, decision for a post-treatment 
renal biopsy should be taken after thorough consideration.  
Furthermore, entering medical records long time after the enrolment in a study may be 
considered a breach of privacy, even if informed consent was obtained at the time of or prior 
to enrolment. Both patients with SLE and non-SLE controls participating in the studies of this 
thesis were fully anonymised in our databases prior to statistical analysis. 
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